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Units:  
 
1.0 µg cadmium = 8.89 nmol cadmium 
 
1.0 nmol cadmium = 0.11 µg cadmium 
 
1.0 µg cadmium/g creatinine ≈ 1.0 nmol cadmium/mmol cadmium  
 
1.0 mg/dL creatinine = 88.4 µmol/L creatinine 
 
1.0 µmol/L creatinine ≈ 0.011 mg/dL creatinine 
 
1.0 pmol/L 1,25(OH)2D ≈ 0.385 pg/mL 1,25(OH)2D 
 
1.0 pg/mL 1,25(OH)2D = 2.6 pmol/L 1,25(OH)2D 
 
1.0 nmol/L 25(OH)D ≈ 0.401 nmol/L 25(OH)D 
 
1.0 ng/mL 25(OH)D ≈ 2.50 nmol/L 25(OH)D 
 
1.0 µmol/L serum retinol ≈ 28.7 µg/dL serum retinol 
 
1.0 µg/dL serum retinol = 0.0349 µmol/L serum retinol 
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ABSTRACT 
Cadmium is toxic and accumulates in the body, particularly in the kidneys. Cereals, 
vegetables and potatoes are the main sources of exposure, besides tobacco smoking. The 
critical effect of cadmium is considered to be renal damage. Massive exposure is known to 
cause osteomalacia and osteoporosis with multiple fractures. A few recent studies have 
indicated that the exposure in the general population is associated with osteoporosis, but the 
link is not clear. 
The aim of this thesis was to investigate effects of long-term low-level cadmium 
exposure on bone health, and to explore whether these effects were mediated via reduced 
activation of 1,25(OH)2D (vitamin D) in the kidney. Another aim was to elucidate possible 
combined effects of cadmium and vitamin A (retinol) on bone health. Two population-based 
studies were used consisting of postmenopausal women, 54 to 69 years of age, with low 
cadmium exposure. Cadmium exposure was assessed by measuring cadmium concentrations 
in urine (as a biomarker of long-term exposure) and by estimating the dietary cadmium intake 
via a food frequency questionnaire. Total-body bone mineral density (BMD) and data on 
fracture incidence (1997-2009) were ascertained. Circulating levels of 1,25(OH)2D and retinol 
were measured in serum. 
Multivariable-adjusted inverse associations were observed between both urinary and 
dietary cadmium and BMD at the total body, femoral neck, total hip and lumbar spine. We 
also observed a statistically significant 2-3 fold increased risk of osteoporosis (T-score <-2.5) 
per µg/g creatinine of urinary cadmium, or per 10 µg/day of dietary cadmium. Among never-
smokers, a several-fold statistically significant increased risk of any first fracture, first 
osteoporotic fracture and first distal forearm fracture was observed for urinary cadmium. A 
30-50% statistically significantly increased risk of any first fracture were observed comparing 
high dietary cadmium intake (≥13 µg/day, median) with lower intakes (<13 µg/day) among all 
women and never-smokers, respectively. Combined high dietary and high urinary cadmium 
(≥0.50 µg/g creatinine) as compared to low, a 3-fold statistically significantly increased risk of 
osteoporosis and fractures were observed among never-smokers.  
 Urinary cadmium was not associated with 1,25(OH)2D and there was no association 
between 1,25(OH)2D and markers of bone or kidney effects. This indicates that the negative 
association between low cadmium levels and BMD was not mediated via decreased 
circulating levels of active vitamin D. Serum retinol concentrations within the normal range 
tended to be associated with higher BMD at the distal forearm. Serum retinol concentrations 
in the upper normal range may counteract the negative effect of cadmium on bone. 
Altogether this thesis provides important evidence that cadmium exposure at the low 
exposure levels found in the Swedish general population is associated with negative effects on 
bone, as indicated by decreased BMD and an increased risk of osteoporosis and fractures. The 
findings are of high public health relevance since the main dietary cadmium exposure is via 
our most important foods, there are no signs of decreasing exposure levels, and that 
osteoporosis and related fractures are prevalent. 
 
ISBN 978-91-7457-446-3
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1 INTRODUCTION  
This thesis focuses on the effects of long-term low level cadmium exposure on bone mineral 
density (BMD) and on risk of osteoporosis and fractures in women. Osteoporosis and 
osteoporotic fractures are important and escalating public health problems. The high incidence 
and the extensive geographical variation (Figure 1) [1] in incidence cannot be fully explained 
by the established risk factors [1-4]. In that context, environmental pollutants have not received 
much consideration. Cadmium is a widespread environmental pollutant that may exert a wide 
range of adverse effects on human health, mainly on kidney and bone [5]. The main source of 
exposure in the general population is food [6, 7], while smokers are additionally exposed. In 
general, women have higher cadmium body burden than men [6, 8], and are also at higher risk 
of osteoporosis and related fractures. Whether cadmium should be considered as a risk factor 
for osteoporosis and fractures remains to be elucidated. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The 10-year probability of hip fractures in men and women adjusted to the probability in 
Sweden [1]. 
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2 BACKGROUND  
2.1 BONE 
The skeleton comprises of over 200 bones, each that is first modeled (sculpted) and then 
remodeled. Depending on the location, the bone supports one or more functions including 
movement and structural support, and also protects vital organs. The skeleton is the main 
reservoir for calcium (about 99% is deposited here including in the teeth) and other minerals 
and is therefore central in the mineral homeostasis [9]. Remodeling constitutes of a delicate 
balance of bone resorption (osteoclasts) and bone formation (osteoblasts). Remodeling is 
important for maintenance of the shape of the bone during growth, to repair injuries and is 
involved in the regulation of serum calcium levels. Osteoblasts produce collagen type 1 (90-
95% of the bone matrix consist of collagen type 1), osteocalcin (the most abundant non-
collagenous protein) and alkaline phosphatase (an organic phosphate-splitting enzyme). Bone 
mainly consists of hydroxyapatite [Ca10(PO4)6(OH)2], which, in turn, comprises 50% of the 
adult bone mass. The hydroxyapatite makes the bone hard while the combination of collagen 
and mineral salts make the bone strong and elastic. The bone mass and calcium metabolism are 
influenced by several factors such as parathyroid hormone (PTH), 1,25(OH)2D (see below), 
oestrogen, calcitonin, and different growth hormones [10].  
 
Bone constitutes of two different tissues; the cortical bone (dense or compact) and the trabecular 
(cancellous) bone, which differ both morphologically and functionally. About 80% of the total 
bone mass constitutes of cortical bone and the remaining 20% constitutes of trabecular bone. 
However, the trabecular bone has a larger surface area than the cortical bone. The cortical bone 
is mainly found in the long bones, while the trabecular is mainly found in the vertebraes (spine), 
the pelvis and at the ends of the long bones. Thus, the relative proportions vary considerably 
among the different skeletal sites. For example is the ratio trabecular:cortical estimated to be 
75:25 in the vertebraes, and 25:75 in femoral neck and distal forearm. The trabecular bone is 
more sensitive to hormonal influences and is considered to have a faster rate of metabolism 
[10]. 
 
2.1.1 Measurements of bone mineral density 
There are several different methods available to measure BMD but the most common one is 
dual energy X-ray absorptiometry (DXA); which is also regarded as the reference standard [11, 
12]. BMD is expressed as grams of mineral per area of volume (g/cm2) and can be measured at 
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total-body and at specific sites such as the distal forearm, femoral neck, hip or spine. When 
measuring BMD, mainly the calcium (i.e. the amount of mineral) in the bone is measured. 
 
By comparing BMD to a reference population, T-score and Z-score can be calculated. T-score is 
used to compare the obtained value to the mean value in young adults of the same sex and is 
calculated as (BMDo - BMDx)/SD where BMDo is the obtained BMD; BMDx the measured 
BMD and SD (standard deviation) in the reference population. T-score is most often used in 
clinical practice. If the purpose is to compare the obtained BMD results with a population with 
of the same age and sex, Z-score is used. A common definition of osteoporosis is T-score <-2.5; 
i.e. 2.5 SD below the mean values of a young adult reference population [13]. 
 
BMD may predict the risk of fractures. A meta-analysis showed that BMD at all measured sites 
had approximately the same predictive abilities [14],  i.e. 1 SD decrease in BMD resulted in a 
relative risk (RR) of a fracture of 1.5 (95% CI, 1.4-1.6). However, the prediction of fracture risk 
was higher when BMD was measured at the specific site of interest, i.e. measurements of the 
BMD at the lumbar spine gave a RR of 2.3 (95% CI, 1.9-2.8) for a fracture at the lumbar spine, 
and BMD measurements at the hip a RR of 2.6 (95% CI, 2.0-3.5) for a fracture at the hip. 
Thus, the predictive ability of 1 SD decrease in BMD for a fracture is similar or better than 
that of 1 SD increase in blood pressure for stroke or 1SD increase in serum cholesterol for 
cardiovascular disease [14]. 
 
2.1.2 Osteoporosis and fractures 
Osteoporosis is “A systemic skeletal disease, characterized by low bone mass and micro-
architectural deterioration of bone tissue with consequent increase in bone fragility and 
increased fracture risk” as defined by the World health organization [13] (Figure 2). The risk of 
osteoporosis relies on the measurement of BMD but the clinical significance lies in the fractures 
that arise [11].  
 
 
 
 
 
 
 
  
 14 
 
 
 
 
 
 
 
 
 
Figure 2. Normal and osteoporotic bone. With permission from the American Society and Bone Mineral Research 
(ASBMR) (1986, Wiley); Dempster and colleagues [15].  
 
Peak bone mass is achieved in the late second decade or third decade. In middle-aged and in 
the elderly the resorption of bone exceeds the formation, leading to loss of bone mass. 
Osteoporosis is reflecting an imbalance of bone formation and bone resorption, in which bone 
resorption dominates. The disease is silent – there are no symptoms – until the first fracture 
occurs. The most common osteoporotic fractures are those at the hip, spine, distal forearm, 
proximal humerus and pelvis [16]. In terms of disability, hip - and vertebral fractures are of 
particular concern [11]. The mortality the first year after a hip fracture is 10-15% [17]. 
 
The incidence of fractures has increased substantially since the 1950ies and is expected to reach 
4,5 million by the year 2050 in Europe [2]. Although a large part of this increase is related to an 
increased ageing population, there is an exceptionally high age-adjusted incidence of 
osteoporotic fractures in certain Western populations [1, 3] such as Sweden and Norway 
(Figure 1), which together with the observed increased incidence over time worldwide, 
underline the need to explore all possible risk factors to enable prevention. In Sweden, every 
other woman and one in four men are statistically expected to have an osteoporotic fracture 
during their lifetime [17, 18]. Every year 70,000 osteoporotic fractures occur in Sweden; out of 
these, about 18,000 are hip fractures and 25,000 are fractures at the distal forearm [17]. In 
Europe, 620,000 hip fractures, 574,000 distal forearm fractures, 250,000 proximal humerus 
fractures and 620,000 clinical spine fractures occur per year, accounting for 35% of worldwide 
fractures [11]. This is of course a major public health concern due to the pain, reduced quality of 
life and life expectancy and the high public health costs associated with the disease [19]. The 
medical cost in Sweden is estimated to 5,6 billion SEK/year (≅1.1% of the total medical cost) 
[16]. In total, including loss of quality-adjusted life year (QALY), the estimated cost is 15 
Normal bone 
 
         Osteoporotic bone 
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billion SEK/year, which is more than the separate medical cost for diabetes or coronary heart 
disease [16].  
 
Genetic factors play a large role for the peak bone mass (about 70%), leaving about 30% or 
more for others factors including environmental factors. Low BMD is the main risk factor for 
fractures, but it alone cannot fully explain all osteoporotic fractures. Other known or proposed 
risk factors for osteoporosis and fractures are for example, older age, female sex, previous low-
energy fracture, smoking, use of glucocorticoids, rheumatoid arthritis, consumption of alcohol, 
low BMI, low physical activity, liver- and kidney diseases, malabsorption, early menopause, 
low intake of vitamin D and calcium, and high and low intake of vitamin A [20, 21]. In this 
context, environmental pollutants such as cadmium including its possible interactions with 
nutrients, have not received much consideration. 
 
The FRAX®-tool has been developed by the WHO to estimate the 10-year probability of 
fracture risk in patients, http://www.shef.ac.uk/FRAX/. The factors considered by FRAX® are 
BMD at the femoral neck, age, female gender, weight, height, previous low-energy fracture, 
parental history of hip fractures, current smoking, use of glucocorticoids, presence of 
rheumatoid arthritis, and consumption of alcohol.  
 
2.1.3 Vitamin D 
Vitamin D belongs to the family of fat-soluble vitamins and was, when discovered in 1922 
primarily considered to be associated with bone health. Vitamin D (25(OH)D) is unique, since it 
can be obtained from both endogenous production of vitamin D3 (in the skin), and exogenous 
sources (mainly D3) from foods such as fatty-fish, fish liver oils, liver, egg yolks and cheese. 
Vitamin D is also present in fortified foods such as low-fat dairy products and in dietary 
supplements. The recommended daily intake in Sweden is 7.5-10 µg/day, but the estimated 
average intake is much lower [22, 23]. Vitamin D status is reflected by the concentrations of 
25(OH)D in serum. During the winter, at Northern latitudes above 40° (Sweden is at latitude 
55-69°), the cutaneous synthesis of pre-vitamin D3 is not detectable [24] and therefore dietary 
sources such as fatty fish and fortified foods (reduced-fat dairy products and margarines), are of 
great importance during these months [22].  
 
Vitamin D coming from the skin or diet enters the circulation and is first metabolized in the 
liver and then converted in the kidney to 1,25(OH)2D - the bioactive form of vitamin D [10]. 
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The role of vitamin D in calcium and phosphate absorption and metabolism is well-known, and 
thus also its importance for bone health. The physiological effect of 1,25(OH)2D is to maintain 
plasma concentrations of calcium and phosphate and also to stimulate osteoblasts to synthesize 
osteocalcin. 1,25(OH)2D primary target tissue is the small intestine, however is also acts on the 
kidney and bone [25, 26].  
 
2.1.4 Vitamin A 
Vitamin A also belongs to the group of fat-soluble vitamins; with the two main groups being 
retinoids or pro-vitamin A. Retinoids include retinol and its metabolites – with retinoic acid 
having the biological activity, exerting its activity via binding to and activation of the retinoic 
acid receptor (RAR). Retinoic acid can also bind to the retinoic X receptor (RXR). With regard 
to pro-vitamin A (e.g. β-carotene), only 10% exert vitamin A activity after first being conversed 
to retinol. In general, vitamin A is important for proliferation and differentiation of cells; and is 
likely to have a role in bone tissue remodelling, since both osteoblasts and osteoclasts express 
RARs.  
 
Vitamin A is obtained from food of animal origin, such as liver and dairy products, and from 
fortified foods, dietary supplements and as pro-vitamin from plant-derived foods [27]. The 
Nordic nutrition recommendation of vitamin A intake is 900 µg retinol equivalents /day for men 
and 800 µg for women [28]. The intake of vitamin A (retinol) from food in Sweden, is generally 
somewhat higher than that recommended [23], mainly due to the fortification of low-fat dairy 
products and margarine. In addition to the dietary intake of vitamin A, dietary supplements 
often contain retinol, and it is estimated that, every third woman and every fifth man in Sweden 
use supplements [29]. Due to recent studies from e.g. Melhus and colleagues; Feskanich and 
colleagues, and Michaëlsson and colleagues [30-32], indicating a higher risk of fractures with 
higher vitamin A intake or higher serum retinol concentrations, the level of fortification and the 
concentration in supplements have been lowered (www.slv.se). On the other hand, normal bone 
metabolism can only be obtained at adequate vitamin A status [33], as also vitamin A 
deficiency is proposed as risk factor for low BMD and fractures [34, 35].  
 
2.2 CADMIUM 
Cadmium is a toxic metal that has no known biological function in the human body. Cadmium 
was discovered in 1817 as an impurity with zinc carbonate, but it was not until the beginning of 
the 20th century that cadmium was more used in the industry. Cadmium has been used as a color 
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pigment (red, yellow, and orange), as stabilizer (e.g. in PVC), cathode in nickel-cadmium 
batteries, and as coating and platings in order to protect other metals or alloys from corrosion. 
The main use of cadmium worldwide in 2005 (82%) was in nickel-cadmium batteries [36]. In 
Sweden, the growing awareness of the adverse health effects of cadmium led in 1982 to a ban 
of use of certain products with the intention to decrease cadmium concentrations in the 
environment. Cadmium is released into the environment due to fossil fuel combustion (e.g. 
coal-fired power plants) where cadmium can be transported long distances from the emission, 
application of sewage-sludge or phosphate fertilizers to farm land, waste incineration and 
disposal, and industrial activity including mining and smelting. Cadmium is easily taken up by 
plants; this uptake is influenced by a number of factors such as pH, competition with other 
metals and presence of inorganic and organic ligands [6]. Cadmium levels have increased in 
Swedish soil during the last century [37] but in spite of restricted use of cadmium in several 
applications since 1982, no decreasing temporal trend in cadmium exposure has been detected 
[6, 37]. 
 
2.2.1 Exposure  
In the general non-smoking population, food is the main source of cadmium exposure. High 
concentrations are present in seafood - such as molluscs, crustaceans, and cephalopods - in 
offals, in oil seeds and cocoa beans [6]. The major contributing foods (80%) are, however, 
cereals - especially whole-grains - vegetables and potatoes [6, 38, 39]; i.e. foods generally 
considered to be healthy which we are recommended to eat more of (www.slv.se). The dietary 
cadmium intake is therefore likely to be higher in certain sub-populations such as vegetarians 
[40]. In areas with cadmium-contaminated soils, house dust may potentially be another 
important route of exposure [41]. Smokers are additionally exposed as a result of the high 
cadmium content of tobacco leaves and the relative high absorption of cadmium in the lungs 
[6, 42].  
 
2.2.2 Uptake and distribution 
Less than 5% of the ingested cadmium is generally considered to be absorbed in the intestine [6, 
7], but the absorption may be several-fold higher at iron deficiency due a common transport 
mechanism of cadmium and iron in the intestine [39, 40, 43-46]. A diet high in fiber, especially 
cereal fiber, which also contains more cadmium than refined wheat flour, might reduce the 
cadmium bioavailability as compared to a low-fiber diet (Berglund et al, 1994). The uptake in 
the lungs is much higher; between 10-50% [6, 42]. After the uptake, cadmium may be bound to 
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albumin in the blood and transported to the liver [6, 42]. Once cadmium is in the liver it induces 
metallothionein (MT) – a low molecular weight cysteine-rich protein – which is important for 
detoxification [42]. MT can also bind essential metals such as copper and. Besides MT, 
cadmium can also bind to amino acids or to sulhydryl-rich low molecular weight peptides [47]. 
Since cadmium-MT is a small complex it can be efficiently filtered through the glomerulus and 
then be reabsorbed in the tubular cells [6, 42]. Cadmium is eliminated very slowly from the 
body and the half-time in the kidney is 10-30 years [42]. Thus, the cadmium concentration in 
the kidney increases with age and may peak around 50->60 years, after which it may start to 
decline [42].  
 
2.2.3 Biomarkers of exposure 
The most feasible and commonly used markers of exposure are cadmium in blood and urine. 
Cadmium in blood, considered the most valid marker of recent exposure is mainly bound to 
erythrocytes and measured in whole blood or in erythrocytes [5]. Two compartments are 
suggested to exist; one is related to the recent exposure and has a half-time of 1-3 months, and 
the other is related to body burden and has a half-time of approximately 10 years [48]. Thus, 
after long-term low level exposure, cadmium in blood may serve as a good marker of cadmium 
body burden [5].  
 
Urinary cadmium, on the other hand, is considered to mainly reflect the kidney accumulation 
[49] (i.e. before onset of tubular proteinuria) and thus the long-term exposure from all sources 
[6, 42]. Ideally, cadmium should be measured in 24-h urine. This is, however, usually not 
feasible in large epidemiological studies for practical reasons, and there in an apparent risk of 
incomplete sampling. Collection of spot urine is more convenient but the dilution of the urine 
may vary considerably both with regard to water and solutes, within and between individuals, 
due to variation in fluid intake, temperature, and physical activity [42]. In order to account for 
this variation the spot urine samples need to be adjusted either for urinary creatinine or for 
specific gravity.  
 
2.2.4 Kidney effects  
Cadmium exposure has been associated with several different health effects such as kidney, 
bone, and cardiovascular effects and cancer [5]. The critical organ for chronic cadmium 
exposure has long been considered to be the kidney and renal dysfunction the critical effect [6, 
7]. Cadmium induces renal tubular damage, characterized by an increased excretion of low-
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molecular weight proteins, such as β-2-microglobulin (β-2-M), α1-microglobulin (also called 
protein HC) and retinol-binding protein (RBP) and increased excretion of the lysosomal enzyme 
N-acetyl-β-D-glucosaminidase (NAG). If the cadmium exposure continues, tubular damage may 
progress and also glomerular damage may emerge, with a decreased glomerular filtration rate 
(GFR). This has been demonstrated in heavily exposed subjects [50-52], but also at much lower 
exposure levels [53].  
 
During recent years, there has been a debate concerning whether the association observed 
between urinary cadmium concentrations and urine-based biomarkers of tubular dysfunction at 
very low exposure levels actually show a causal relationship. If causal, the public health 
significances of these associations need further evaluation [37], as it has been difficult to 
ascertain the exact lowest dose for what could be considered a clear adverse effect.  
 
2.2.5 Bone effects 
Cadmium’s adverse effect on bone became obvious when the Itai-itai disease (Ouch-Ouch) was 
discovered in the Toyama Prefecture in Japan, more than 50 years ago. This painful disease 
mainly affected women over 40 years of age that had lived in the area for more than 30 years. 
The consumption of heavily contaminated rice resulted in severe renal and bone damages 
followed by multiple fractures [5]. The effects on bone were a combination of osteomalacia and 
osteoporosis. In 1968, the Japanese Ministry and of Health and Welfare concluded that “Itai-itai 
disease is caused by chronic cadmium poisoning, on conditions of existence of such inducing 
factors as pregnancy, lactation, imbalance in internal secretion, aging, and deficiency of 
calcium” [54]. Approximately 200 subjects were affected and their urinary cadmium 
concentrations were very high ( ≈ 30 nmol/mmol creatinine).  
 
First in 1999, the association between cadmium exposure and osteoporosis was examined again 
[55]. In a prolongation of the ground-breaking CadmiBel study [56] with baseline data (1985-
1989) on cadmium in urine, soil and garden vegetables, associations were assessed with BMD 
at the forearm (SXA) and with incidence of fractures and height loss in 506 women and men. 
Participants were from cadmium-contaminated areas close to zinc smelters and in control areas 
in Belgium. Cadmium in urine, leek and soil was inversely associated with BMD at the forearm 
in postmenopausal women, but not in men. For a doubling of urinary cadmium, an increased 
risk of fractures at the forearm in women was observed, relative risk (RR) of 1.73 (95% CI, 
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1.16-2.57) (p=0.007), and height loss in men, RR, 1.60 (95% CI, 0.94-2.72) (p=0.08) [55]. 
Noteworthy, if age was forced into the multivariable-adjusted model, the increase in RR for 
urinary cadmium was no longer statistically significant (p=0.08). In both women and men, soil, 
leek and celery were associated with a similar increased risk of fractures (p≤0.039) as for 
urinary cadmium. For height loss, cadmium in leek was associated with an increased risk in 
both women and men (p≤0.005), while cadmium in soil and celery were only associated with 
increased risk of height loss in women (p≤0.035).  
 
The association between cadmium exposure and bone was confirmed in a Swedish population 
(n=1021; women and men) living in the proximity of a nickel-cadmium battery plant. Alfvén 
and colleagues found an increased risk of osteopenia (Z-score <-1) and fractures at the distal 
forearm at urinary cadmium concentrations between 0.50-3 µg/g creatinine, and 2-4 µg/g 
creatinine, respectively [57, 58]. Some of the participants were occupationally exposed at the 
battery plant. In studies from heavily polluted areas in China, associations were also observed 
between cadmium exposure and osteoporosis [59, 60]. When this thesis was initiated only a 
limited number of studies were available and only one study had examined the association 
between cadmium and bone at the low exposure levels present in the general “non-exposed” 
population [61]. In upper middle-aged women in Southern Sweden (Women’s Health in the 
Lund area, WHILA) and inverse association was observed between cadmium in urine, but not 
in blood, and BMD at the distal forearm; the median urinary cadmium concentration was 0.67 
µg/g creatinine. In 2008, Schutte and colleagues found similar associations in a population with 
environmental cadmium exposure mainly from zinc smelters in Belgium [62]. The studies from 
Schutte and colleagues, and Åkesson and colleagues suggest a direct effect of cadmium on 
bone, with increased concentration of bone resorption markers with increasing cadmium 
exposure, possibly intensified after menopause. Exposure to cadmium was also associated with 
calciuria and with reactive changes in calciotropic hormones [62]. Because cadmium was 
associated with lower levels of PTH in both studies, the cadmium-associated calciuria was most 
likely a result of increased bone resorption, rather than decreased tubular reabsorption followed 
by an increase in parathyroid hormone [62]. 
 
Only one previous study comprising 2,826 women, aged 50 to 90 years, have examined the 
association between cadmium and BMD outside the site of the distal forearm [63]. An inverse 
association was observed between urinary cadmium and BMD at the femoral neck and total hip, 
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and an increased risk of osteoporosis at the total hip [63]. This study (Gallagher et al, 2008) and 
another study from the United States [64], are the only ones that have presented separate 
associations for never-smokers. Wu and colleagues [64], but not Gallagher and colleagues [63], 
observed a significant dose-response relationship. Only one study has assessed BMD at the 
lumbar spine. Nawrot and colleagues, observed a non-statistically significant inverse association 
(p=0.14)  between urinary cadmium and BMD at the lumbar spine in in men occupationally 
exposed [65]. Although several studies have found adverse associations between cadmium 
exposure and bone, there are a few studies reporting non-significant associations or even null 
findings [66-69]. Thus, there is a need to clarify the role of cadmium in development of 
osteoporosis, especially focusing on sites particular susceptible to osteoporotic fractures with 
high public health importance. Even more important is of course the evaluation of fracture risk. 
It is also essential to rule out any possible non-cadmium mediated negative effect of tobacco 
smoking on bone. Although food is the main source of exposure in most people the relation 
between the dietary cadmium intake and BMD or osteoporosis has never been explored.  
   
2.2.6 Vitamin D, cadmium and bone 
The mechanism of cadmium-induced bone damage is not yet fully understood. Two main 
hypotheses have been suggested: a direct effect on the skeleton possibly through activation of 
osteoclasts and ii) an indirect effect, via an initial kidney damage, inhibiting the conversion of 
25-hydroxy vitamin D (25(OH)D) to 1,25-dihydroxy vitamin D (1,25(OH)2D) [70]. The 
accumulation of cadmium in the renal cortex has been proposed to interfere with enzymes either 
directly or indirectly involved in this conversion of 25(OH)D to 1,25(OH)2D. In addition, 
cadmium may decrease the tubular reabsorption of elements necessary for proper bone 
metabolism, such as calcium, resulting in increased excretion of these elements in urine. 
Concerning the effect of cadmium on 1,25(OH)2D activation, several experimental studies have 
shown inconsistent results at cadmium concentrations relevant to human exposure [70]. Even 
though the limited number of available human studies suggests lower serum 1,25(OH)2D 
concentrations at high cadmium exposure [71-74], the results are inconclusive. Furthermore, as 
most of the included subjects were already severely affected by cadmium-induced renal 
dysfunction [71-74], nothing is known about its involvement in the early onset of bone effects.  
 
2.2.7 Vitamin A, cadmium and bone 
Experimental studies have shown that high retinoic acid concentrations and also high 
concentrations of cadmium seem to give raise to teratogenic effect on limb formation [75]. 
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One study has also shown that cadmium may induce the biosynthesis of retinoic acid via up-
regulation of genes that are involved in the retinoic acid metabolism as well as an inhibition 
of enzymes that are involved in the degradation of retinoic acid [76]. Studies on vitamin A in 
humans have shown inconsistent results with regard to associations with BMD and fracture 
risk. There is no data in humans on possible combined effect of vitamin A and cadmium on 
bone. 
 
2.2.8 Risk assessment  
For extensive risk assessments on cadmium, see reports from the European Food and Safety 
Authority (EFSA) [6] and the Joint FAO/WHO Expert Committee on Food Additives 
(JECFA) [77-80]  (www.fao.org/es/esn/jecfa).  
 
The JECFA established already in 1972 a provisional tolerable weekly intake (PTWI) for 
cadmium of 7 µg/kg body weight (bw)/week (60 µg/day for an individual of 60 kg) [77]. In 
1988 and 2005, the PTWI was re-evaluated and retained [78, 79]. In 1992, WHO concluded 
that a urinary cadmium excretion of 10 µg/g creatinine caused tubular proteinuria in 10% in 
the population [7].  
 
In 2009, a risk assessment was performed by EFSA. A new tolerable weekly intake (TWI) 
was established; 2.5 µg/kg bw [6] corresponding to 25 µg/d at 70 kg bw. This new TWI was 
set to keep 95% of the population by the age of 50 below the “reference point” of 1 µg 
cadmium/g creatinine in urine. The TWI is close to the mean dietary exposure for adults in 
Europe, but may be exceeded by specific subgroups such as vegetarians, children, smokers 
and subjects living in contaminated areas.  may exceed this TWI with about 2-fold [6].  
 
In 2010, JECFA withdrew their PTWI and expressed a new tolerably monthly intake (PTMI) 
of 25 µg/kg bw (also corresponding to ≈60 µg/day at 70 kg bw) based on a reference point of 
5.4 µg cadmium/g creatinine [80]. Thus, EFSA and JECFA came to very different conclusion 
on the reference point 1vs 5.4 µg/g creatinine (based on the same meta-analysis of urinary 
cadmium and the tubular effect marker β-2-M). Other differences concerned the statistical 
methods used to account for uncertainty and variability (JECFA did not account for inter-
individual variations), and the methodology for transforming urinary cadmium to dietary 
cadmium intake. EFSA concluded that their TWI at 2.5 µg/kg bw should be maintained [81, 
82].  
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3 AIMS OF THE THESIS 
The overall aim of this thesis was to explore whether long-term low-level exposure to the toxic 
metal cadmium adversely affects the bone health in women.  
 
The specific objectives were: 
  To assess the associations between urinary cadmium and:   
• bone mineral density (BMD) and risk of osteoporosis at sites particularly susceptible to 
osteoporotic fractures (Paper I) 
• risk of fractures, assessed as any first fracture, any first osteoporotic fracture, the most 
common osteoporotic fracture (distal forearm), and multiple fractures (Paper I) 
 
 To determine the association between questionnaire-based dietary cadmium exposure and 
BMD and risk of osteoporosis and fractures (Paper II) 
 
 To explore whether the inverse association between cadmium exposure and BMD is 
mediated via reduced activation of 25(OH)D to 1,25(OH)
 2D, as assessed by the circulating 
concentrations in serum (Paper III) 
 
 To elucidate possible interactions between cadmium and vitamin A on bone, through 
measurements of biomarkers of exposure, BMD and biochemical markers of bone turnover 
(Paper VI) 
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4 SUBJECTS AND METHODS 
The following is a summary of the study populations and methods used in this thesis. Further 
details can be found in each respective paper (I-IV). 
 
4.1 STUDY POPULATIONS AND SAMPLING 
Data from two population-based epidemiological studies are used in this thesis: 
 The Swedish Mammography Cohort (SMC) (Paper I and II) 
 The Women’s Health in the Lund Area (WHILA) (Paper III and IV)  
 
4.1.1 Swedish Mammography Cohort (SMC) 
The Swedish Mammography Cohort (SMC) was established in 1987-1990 with the general aim 
of assessing the relationships between a number of modifiable factors and the occurrence of 
several major chronic diseases (http://www.imm.ki.se/smc/). All 90,303 women, born between 
1914 and 1948 and residing in two counties (Uppsala and Västmanland) in central Sweden 
received an invitation to be screened by mammography. Enclosed with this invitation was a 
six-page questionnaire covering information on dietary habits (food frequency questionnaire, 
FFQ), weight, height, parity and education; 66,651 (74%) of the women completed the 
questionnaire [83].  
 
In 1997, a more comprehensive questionnaire was sent out to all 56,030 women still living in 
the study area, with extended questions on dietary habits (FFQ) and with collection of 
information on reproductive factors including use of postmenopausal hormones, physical 
activity, education, smoking history and medical history of certain diseases. A completed 
questionnaire was obtained from 38,984 women (70% response rate) [83].  
   
4.1.1.1 SMC sub-cohort 
In the present thesis (Paper I and II), the association between cadmium exposure and BMD, 
osteoporosis and fractures were studied in a sub-cohort of the SMC consisting of women living 
in the town of Uppsala. Since 2003, the women were invited to complete a detailed 
questionnaire on diet and lifestyle factors, and to undergo a health examination at 
Samariterhemmet in Uppsala. The examination was conducted after overnight fasting and 
included total-body BMD measurements (DXA), weight and height measurements, sampling of 
fat tissue, blood, and from 2004 also morning spot urine.   
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 The recruitment continued until early September 2009, when in total 8,311 women had been 
invited (65% responded and completed the FFQ). In total, 5,022 women (aged 54-85 years) 
underwent BMD measurements (60%). For Paper I and II, we included women who had been 
recruited until the end of December 2008 and by that time 4,718 women had undergone BMD 
measurements, 4,276 had provided urine samples for cadmium analysis and 4,575 women had 
filled in the questionnaires. Out of these women, 2,820 were below 70 years of age (at time of 
clinical examination), which was the age limit chosen for the cadmium study in order to avoid 
an inverse effect of old age on kidney cadmium accumulation [84]. For additional exclusion 
criteria, see Figure 3.  
 
4.1.2 Women’s Health in the Lund Area (WHILA) 
All women 50 to 59 years of age and living in the Lund area by December 1st, 1995 (n = 
10,766) were invited to a health screening program (participation rate 64%; n=6,917) [85]. 
Together with the invitation, the women received a basic questionnaire including questions on 
previous and present diseases, drug treatment, smoking- and alcohol habits, education, physical 
activity, working status, parity, months of lactation, and menopausal status [86]. The women 
underwent measurements of forearm BMD (DXA), weight, height and minimal waist- and 
maximum hip circumference [85].  
 
4.1.2.1 The cadmium-study in WHILA 
In June 1999, when 1,160 women remained to be invited, the study was extended to include 
health aspects of cadmium exposure; 820 women (aged 54 to 63 years) participated (71%). Out 
of these women, 813 provided a morning urine sample and 742 women a blood sample [53, 61]. 
Because urinary cadmium was inversely associated with BMD in these women (Åkesson et al., 
2006), we wanted to explore whether this association was mediated via a decreased activation in 
the kidneys of vitamin D, as assessed by the concentration of 1,25(OH)2D in serum (Paper III). 
Further, in order to elucidate a possible interaction between cadmium and vitamin A on the 
effects on bone (Paper IV), we analysed vitamin A (retinol) in serum. Thus, for the purpose of 
Paper III and IV we used, as previously measured and described elsewhere, cadmium in urine 
and blood and several biochemical markers of bone turnover such as parathyroid hormone 
(PTH), bone alkaline phosphatase (bALP), and osteocalcin in serum and deoxypyridinoline 
(DPD) in urine, as well as kidney effect markers: serum cystatin C, urinary N-acetyl-β-D-
glucosaminidase (NAG) and urinary protein HC (α1-microglobulin) [53, 61]. For exclusion 
criteria (Paper III and IV), see Figure 3.  
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820 women participated 
WHILA (1999-2000) cadmium-study 
1,160 women residing in the Lund area  
Source Subcohort (2003-2009) 
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energy intake 
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residing in the Lund area (64% participated) 
 
Excluded (n=204) 
•  Hypo/hyperparathyroidism 
•  Rheumatoid arthritis 
•  Renal cancer 
•  Users of oral corticosteroids  
•  Users of lithium  
•  Liver disease 
•  No remaining serum 
Excluded (n=132) 
with diabetes 
SMC Subcohort (2004-2008) cadmium-study 
2,820 women <70 years of age 
SMC WHILA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The Swedish Mammography Cohort (SMC) and Women’s Health in the Lund Area (WHILA), source populations and study populations for 
Paper I-IV. Figure: Magga-Rita. 
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4.2 BIOMARKERS OF EXPOSURE AND EFFECT 
4.2.1 Element analyses (Paper I-IV) 
In order to assess the long-term exposure to cadmium we used urinary cadmium, as this 
reflects accumulation of cadmium in kidneys over decades [42]. In non-smokers urinary 
cadmium is likely to mainly reflect the dietary cadmium exposure. We also measured calcium 
and magnesium in urine since they are important for bone structure [10]. In Paper III, we 
also used available data on blood cadmium concentration, mainly reflecting the short-term 
exposure [53, 61].  
 
The participating women in the SMC-subcohort received by mail a cup (previously tested free 
from metal contamination) to collect the first voided morning urine sample and a 13-ml 
polyethylene tube (acid-washed, Sarstedt, Nümbrecht, Germany) for storage of the urine. A 
detailed sampling instruction was included to minimize the risk of contamination of the urine 
(Paper I and II). The women brought the urine sample to the clinical examination at 
Samariterhemmet, Uppsala City (SMC). A similar procedure was used for the collection of 
urine samples in Paper III and IV (WHILA).  
 
4.2.1.1 Cadmium analyses  
All laboratory utencils for the urinary analysis, such as tubes and tips (polyethylene; Sarstedt, 
Nümbrecht, Germany) were acid-washed. Urinary cadmium was measured at the Institute of 
Environmental Medicine (IMM), Karolinska Institutet (KI), using inductively coupled plasma 
mass spectrometry with a collision/reaction cell operated in helium-mode (ICPMS; Agilent 
7500ce, Agilent Technologies, Waldbronn, Germany) [87], measuring cadmium isotope 111 
(m/z 111) in all samples (Paper I and II). Helium mode was used in order to minimize 
polyatomic interferences; mainly by molybdenum oxide.  
 
For analysis, the urine sample was diluted 1:10 with 1% HNO3 (nitric acid) (suprapur, Merck, 
Darmstedt, Germany). In order to evaluate the analytical accuracy for cadmium, several 
appropriate reference materials were included in the analyses (Table 1 and Figure 4). In 
general, the results of all the reference materials were in good agreement with the reference 
values (CV <15%). One exception was, however, the cadmium concentrations of Seronorm 
OK4636 (Seronorm Trace Elements Urine Blank, REF 201305; SERO AS, Billingstad, 
Norway), which was consistently somewhat lower than the recommended value, also observed 
by others. However, two certified standard reference materials (CRM; National Institute of 
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Standards and Technology (NIST), Gaithersburg, MD, USA) and an additional Seronorm 
(101021; aiming at same concentrations as OK4636) were included. All these showed very 
good agreement with the reference values. The low CRM (reference value 0.059 ± 0.0034 µg/L) 
aimed at assuring the analytical quality at very low cadmium concentrations. In total only 35 
urine samples were below the reference value for this low CRM (<0.059 µg/L). The mean limit 
of detection (LOD), calculated as 3 x standard deviation (SD) of the mean blank values was 
0.002 µg/L, which is the lowest LOD published. No samples had cadmium concentrations 
below the LOD; the lowest urinary cadmium concentration in the women was 0.02 µg/L. In 
addition to all the reference material, we also included one “in house” control urine sample 
(treated in the same way as the urine samples from the women), which showed good 
repeatability (Figure 4). In total, we performed 18 runs (Table 1). Altogether, the rigorous 
quality program and the high analytical precision ensured that the measured urinary cadmium 
concentrations are valid and that the uncertainty is low even in the low dose range (Table 1 and 
Figure 4).  
 
In order to account for variation in urine dilution, all cadmium concentrations were adjusted for 
urinary creatinine (µg/g creatinine; Clinical Chemistry, Västerås Hospital, Västerås, Sweden) 
as well for urinary density (g/mL) (IMM, KI). Urinary density was measured with 
refractometer (URICON-NE refractometer, Atago Co., Ltd, Tokyo, Japan). The mean urinary 
density in the SMC sub-cohort was 1.015 g/mL.  
 
In Paper III and IV (WHILA), ICPMS (Thermo X7, Thermo Elemental, Winsford, United 
Kingdom) was also used for cadmium measurements in urine and blood, under strict quality 
control [53, 61]. These analyses were performed at the Department of Occupational and 
Environmental Medicine, Lund University, Sweden. The LOD for urinary cadmium was 0.31 
µg/L and 0.12 µg/L for blood cadmium [53] with 172 urine (22%) and 3 blood samples 
(0.4%) below LOD, respectively. For samples below LOD the actual obtained concentrations 
were used in the calculations, although the concentrations below LOD are measured with a 
higher uncertainty as compared to those above LOD. In contrast to the ICPMS method in 
Paper I and II, no collision/reaction cell was used. Thus, we cannot rule out possible 
influence of molybdenum oxide. Urinary cadmium concentrations were adjusted for urinary 
creatinine (µg/g creatinine) as well as urinary density (mean urinary density of 1.015 g/mL in 
WHILA).   
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4.2.1.2 Calcium and magnesium analyses  
In Paper I (SMC), calcium (m/z 43) and magnesium (m/z 25) were measured in urine with 
ICPMS at the same occasion as cadmium. As for cadmium, the same commercial reference 
materials were used to assure quality-control; see Table 1 for details. The mean LOD for 
calcium was 8.0 µg/L and for magnesium 1.1 µg/L. In general, the obtained concentrations 
were in agreement with the reference values, with the exception of Seronorm 101021 for 
magnesium, for which the obtained concentrations were approximately 1/3 of the reference 
value. However, these obtained concentrations were very stable and had a low CV. The reason 
for the discrepancy is not known but it should be noted that Seronorm references are not 
certified. As the results for magnesium in all other reference materials were well within the 
target values, we are confident that we have adequate evidence of accurate analytical results. 
 
In Paper III (WHILA), calcium in urine was measured with ICPMS in Lund [53, 61]. The 
LOD was 1.6 mg/L with 1 sample <LOD.  
 
Table 1. Obtained concentrations (mean±SD) and reference values in urine for the reference 
material used to ensure quality control (Paper I). No reference value is available for the “in 
house” urine sample.
Reference materials n Obtained value Reference value CV (%) 
Cadmium 
    
NIST, low, CRM (µg/L)  18 0.070 ± 0.0092  0.059 ± 0.0034 13 
NIST, high, CRM (µg/L)  18 5.2 ± 0.061  4.7 ± 0.084 1.2 
In house control sample (µg/L)  157 0.79 ± 0.05 - 5.8 
Seronorm, OK4636 (µg/L)  214 0.23 ± 0.04 0.31 ± 0.05 15 
Seronorm, NO2525 (µg/L)  130 4.7 ± 0.19 5.1 ± 0.22 8.0 
Seronorm, 101021 (µg/L)  21 0.37 ± 0.03 0.35 ± 0.08 4.1 
     
Calcium     
NIST, low, CRM (µg/L)  18 30 ±3.2  30 ± 2 11 
NIST, high, CRM (µg/L)  18 30 ± 2.7 29 ± 2 9.0 
In house control sample  (µg/L)  157 17 ± 1.5 - 8.8 
Seronorm, OK4636 (µg/L)  214 125 ± 10 116 ± 6 8.0 
Seronorm, NO2525 (µg/L)  130 118 ± 10 108 ± 4 8.7 
Seronorm, 101021 (µg/L)  21 137 ± 12 130 ± 2 8.7 
     
Magnesium     
NIST, low, CRM (µg/L)  18 19 ± 1.9 21 ± 0.2 10 
NIST, high, CRM (µg/L)  18 20 ± 1.9  21.2 ± 0.2 9.5 
In house  control sample (µg/L)  157 15 ± 1.2  - 8.0 
Seronorm, OK4636 (µg/L)  214 86 ± 8.9  89 ± 4 10 
Seronorm, NO2525 (µg/L)  130 56 ± 3  54 ± 3 9.0 
Seronorm, 101021 (µg/L)  21 59 ± 5.3 185 ± 40 9.1 
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Figure 4. Obtained cadmium results for low CRM, “in house” control sample, Seronorm OK4636 and Seronorm 101021. 
   
  
  31 
4.2.2 Vitamin D analyses (Paper III) 
In Paper III (WHILA), we assessed 1,25(OH)2D in serum as a marker of the activation 
of 25(OH)D to 1,25(OH)2D using an enzyme immunoassay (EIA). Immunoextraction 
was followed by quantification (IDS OCTEIA Ltd., Boldon, United Kingdom). These 
analyses were performed at IMM, KI. The EIA quantified the two forms 1,25(OH)2D3 
(cross-reactivity 100%) and 1,25(OH)2D2 (cross-reactivity 39%). The sensitivity was 6 
pmol/L and the assay ranged from 4 to 500 pmol/L. Because of the cumbersome and 
expensive assessment of 1,25(OH)2D, we selectively analysed 45 women with low 
urinary cadmium concentrations and 40 women with high urinary cadmium 
concentrations. In addition, we analysed 25(OH)D (EIA) in 42 women (n=22 with low 
urinary cadmium and n=20 with high urinary cadmium) in order to exclude a possible 
effect on the concentration of 1,25(OH)2D due to differences in vitamin D status [26]. 
Samples for vitamin 25(OH)D analyses were collected during winter season to avoid 
major influence on the concentration of variations in sunlight exposure [88]. The 
corresponding cross-reactivity for 25(OH)D was 100% for 25(OH)D3 and 75% for 
25(OH)D2. The results of the provided control samples from the manufacturer were 
within the recommended range. One “in house” serum control sample was included in a 
similar manner as the analysis of urine samples. The CV for the three control samples, 
including the” in house” sample, for 1,25(OH)2D were 6.2%, 7.1% and 9.2% and for 
25(OH)D 8.1%, 4.7% and 5.9%, indicating good analytical accuracy.  
 
4.2.3 Retinol analysis (Paper IV) 
In Paper IV (WHILA), serum retinol was measured in order to evaluate the retinol 
status. These analyses were performed at IMM, KI. Since vitamin A is sensitive to 
degradation from UV-light, all the windows and strip-lights were shielded with special 
UV-filters. The concentrations of retinol in serum were assessed in 606 women 
(WHILA) by high pressure liquid chromatography (HPLC) followed by fluorescence 
detection (excitation 325 nm; emission 475 nm) [89]. Retinyl acetate and retinol 
(external standards) were used for quantification. The stock solution, including retinyl 
acetate and retinol was checked every morning for degradation and samples from the 
stock solution was prepared fresh every morning. All the samples were analysed in 
duplicates. The CV for the “in house” control sample was 13%, indicating a 
satisfactory analytical accuracy. 
 
 32 
4.2.4 Bone and kidney markers  
We used the previously measured bone turnover markers parathyroid hormone (PTH), 
bone alkaline phosphatase (bALP), osteocalcin and urinary deoxypyridinoline (DPD) 
and the kidney effect markers serum cystatin C, N-acetyl-β-D-glucosaminidase (NAG) 
and urinary protein HC (α1-microglobulin) [53, 61].  
 
4.3 DIETARY ASSESSMENT 
A comprehensive food-cadmium database (recipe-based) has been constructed at IMM, 
KI based on the cadmium content present in almost all foods available on the Swedish 
market [38, 90]. With few exceptions, the food cadmium data were obtained from the 
National Food Administration (Uppsala, Sweden). The daily cadmium intake was 
estimated by multiplying the cadmium content with the consumption frequency and 
specific portion sizes, based on the FFQ and the food-cadmium database. The FFQ has 
previously been validated against weighted food records (Pearson correlation 
coefficients of 0.5-0.8 for the major cadmium containing food groups; Wolk, 
unpublished data).  
 
For paper II, the cadmium intake estimated from the FFQ in 1997 was used to assess 
the association between dietary cadmium exposure and bone effects. The FFQ from 
2004-2008 completed at the time of the urine sampling was not considered since it does 
not to reflect the relevant time period of the exposure in relation to the bone 
measurements. In addition, this enabled the risk of fractures to be assessed 
prospectively with follow-up starting in 1997 (Paper I and II; SMC).   
 
The intakes of calcium, magnesium, fiber and iron, which all may influence bone 
health, were also obtained from the FFQ. Cadmium, calcium, magnesium, fiber and 
iron were energy adjusted (to 1700 kcal; mean in the cohort) by using the residual 
method [91]. Energy-adjustment is consistently used in nutritional epidemiology and is 
a way to compensate for possible under- or over reporting of intake. The approach is 
based on the concept that the composition of the diet, independent of the energy intake, 
is of primary interest in relation to disease risk. Energy-adjustments can limit 
misclassification of the cadmium/nutrient intake due to differences in body size, 
physical activity etc. [91]. 
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4.4 BONE MEASUREMENTS  
4.4.1 BMD 
In Paper I and II (SMC), we used data on BMD (g/cm2) measured with DXA (DPX 
Prodigy, Lunar corp., Madison, WI, USA) at Samariterhemmet, Uppsala [92]. BMD 
was measured at the total body, femoral neck, total hip and lumbar spine (vertebrae L2-
L4) (Figure 5). In Paper I, 2.0% of the women and 1.6% of the women in Paper II 
had only one-sided measurements done at the femoral neck due to metal implant (e.g. 
prosthesis or plate). However, in order to keep as many women as possible in the 
analyses, these women were also included. In all other women, the mean BMD of both 
sides were used.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Sites measured at the BMD measurements at Samariterhemmet, Uppsala (Paper I 
and II; SMC). Figure: Magga-Rita. 
 
 
4.4.2 Osteoporosis  
The obtained BMD was compared to the mean value in a reference population (aged 20 
to 29 years) from the National Health and Nutrition Examination Survey (NHANES) 
[93]. Osteoporosis was defined as a T-score <-2.5. The one and the same technician 
performed the BMD measurements, and a phantom was used every day for internal 
validation. The precision error for the BMD measurements was very low (0.8-1.5%). 
The long-term CV precision for lumbar spine was <1%. At the DXA measurements, 
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total fat mass and total lean body mass were also measured with high precision (for 
details, see Paper I).  
 
In Paper III and IV (WHILA), BMD was measured at the non-dominant distal 
forearm (at the 8 mm position), using DXA (DXT 200; Osteometer MediTech, Inc., 
Hawthorne, CA, USA) as previously reported [61, 85, 86]. As for SMC, the one and the 
same technician in the WHILA study performed all the measurements and a phantom 
was used for daily calibration. 
 
4.4.3 Fractures 
We obtained information of eligible fractures for Paper I and II (SMC) by 
computerized linkage of the cohort, using the personal identification number given to 
all Swedish citizens, with the regional hospital diagnosis registries and to the National 
Patient Registry, thereby covering both outpatient and inpatient treated fractures [94]. 
The codes used were from ICD-10 and included S12, S22, S32, S42, S52, S62, S72, 
S82 and S92 (all fractures) [94]. The classical osteoporotic fractures were considered as 
fractures at the hip, spine, distal forearm, proximal humerus, and pelvis; the most 
common first osteoporotic fracture was distal forearm. A validated method for 
multiple fractures (that is, multiple incident fracture occasions) was used to identify 
the incident injuries from the resubmissions [95]. 
 
4.5 ETHICS 
Oral or written informed consent regarding participation was obtained from all women. 
The ethical committees at Lund University in Lund, Sweden and the Regional Ethical 
Review Board in Stockholm, Sweden approved the studies. The results of the BMD 
measurements were reported to the women at their clinical visit and those women with 
low BMD were directed to practitioners for further investigation.  
 
4.6 STATISTICAL METHODS AND ANALYSES  
For univariate associations, Spearman rank correlation coefficient (rs) was used for 
continuous variables and Kendall’s tau_b for categorical variables. Mann-Whitney U-
test, Kruskal-Wallis or χ2-test were used to assess the differences between independent 
groups. In order to account for the influence of other factors we performed 
multivariable-adjusted regression analyses. The residual analysis indicated no major 
deviation from a linear pattern in the linear regression. Odds ratio (OR) and its 95% 
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confidence interval was achieved by using logistic regression. Multicollinearity was 
tested with tolerance (>0.1) and variance inflation factor (VIF, <10) for both linear and 
logistic regression. Binary logistic regression models were tested for Hosmer-
Lemeshow (>0.05) and ordinal logistic regression for a Pearson goodness-of-fit and 
proportional odds assumption (>0.05).   
 
In Paper I (SMC), several different statistical analyses were used to assess the 
relationship between urinary cadmium and BMD, osteoporosis and fractures. We used 
linear regression analyses, analysis of covariance (ANCOVA), and binary- and ordinal 
logistic regression analyses. Additionally, restricted cubic spline analyses (with three 
“knots”) were used in order to make the model flexible, and also to be able to 
graphically show the association between urinary cadmium and risk of osteoporosis 
[96]. Urinary cadmium was treated either as a continuous variable (per 1 µg/g 
creatinine or per 0.42 µg/g creatinine (=2 SD) increment) or as a categorized variable 
into predefined groups or into tertiles. The predefined categories were <0.50, 0.50-0.75 
and ≥0.75 µg/g creatinine to facilitate comparison with previous studies [57, 63] using 
concentrations of <0.50 µg/g creatinine as the reference category. Because few women 
had urinary cadmium >1 µg/g creatinine (n=46) in SMC, a middle exposure category 
(0.50-0.75), which in contrast to previous studies had to be included. Trend across 
categories was tested using the median urinary cadmium within categories as a 
continuous variable in order to avoid giving too much weight to potential outliers. 
 
In Paper II (SMC), estimated dietary cadmium exposure was either continuously 
treated as per 10 µg/day increment or in 2 categories; below (low) or above the median 
(high) dietary cadmium intake (< and ≥13 µg/day). The relationship between dietary 
cadmium and BMD, osteoporosis and fractures were analysed with linear and binary 
logistic regression analyses. Dietary factors important for bone health and cadmium 
bioavailability (calcium, magnesium, iron and fiber) were additionally included in order 
to examine if these would attenuate the associations between dietary cadmium and 
BMD and fractures. The combined effect of dietary cadmium (low or high) and urinary 
cadmium (<0.50 or ≥0.50 µg/g creatinine) were assessed by combining the high dietary 
cadmium category with the high urinary cadmium category. Women with low dietary 
cadmium intake and low urinary cadmium excretion constituted the reference category 
while the remaining women were categorized into the
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In Paper III (WHILA), univariate analyses evaluated the relationship between 
1,25(OH)2D and several exposure- and effect markers. Linear regression analyses were 
used to evaluate the relationship between 1,25(OH)2D and urinary- or blood cadmium.  
 
In Paper IV (WHILA), univariate and linear regression analyses were used. A 
potential non-linear association between serum retinol and BMD was evaluated by 
additionally adding squared serum retinol to the model. In addition, a multivariable-
adjusted scatterplot was calculated in order to visually observe a possible non-linear 
trend between serum retinol and BMD. Urinary cadmium was subsequently added to 
the statistical models evaluating the association between retinol and BMD and bone 
turnover markers. To evaluate a possible combined effect, serum retinol and urinary 
cadmium were categorized into 2 groups: below (low) and above (high) the median (< 
and ≥1.9 µmol for serum retinol; < and ≥ 0.66 nmol/mmol creatinine for urinary 
cadmium). Women having the lowest serum retinol and the highest urinary cadmium 
had the lowest BMD and therefore constituted the reference category, while the 
remaining women were categorized into high/high, low/low and high/low 
concentrations of retinol and urinary cadmium, respectively. This association was 
analyzed with linear regression.  
 
The covariates included in the statistical models  in Paper I-IV were selected if 
associated with both the exposure and the outcome, changing the estimate for the 
exposure in the multivariable-adjusted model by more than 10% and/or are traditionally 
known protective- or risk factors for BMD and fractures. For more details on the 
included variables; see the separate papers. 
 
The statistical analyses were carried out using SPSS (PASW), version 14 or 18.0 (SPSS 
Inc., Chicago, IL, USA), Stata 10.1 (Stata Corporation, Inc., Collage Station, TX, 
USA) and Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA). All 
tests were two-sided, and a p<0.05 was considered statistically significant. 
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5 RESULTS AND DISCUSSION 
This section is a summary and discussion of the main results and conclusions that can 
be drawn. For further details, the reader is referred to the separate Papers (I-IV). Some 
additional results are included that are not reported in the Papers. 
 
5.1 CADMIUM EXPOSURE 
5.1.1 Biomarkers of exposure 
The median urinary cadmium concentration in the 2,688 women from the SMC (Paper 
I-II) was 0.34 µg/g creatinine (second black line from the bottom in Figure 6). The 
median concentration in 606 women in the WHILA study (Paper IV) was 0.66 µg/g 
creatinine (second grey line from the bottom; p<0.001 for difference between studies). 
The exposure categories used in Paper I, II and IV are also indicated in Figure 6. In 
the WHILA study, 70% of the women had urinary cadmium concentrations >0.50 µg/g 
creatinine as compared to 23% in the SMC. The corresponding percent for cadmium 
concentrations above >1.0 µg/g creatinine was 20% and 0.2%, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Comparison of urinary cadmium (µg/g creatinine) in the SMC and WHILA studies 
(all women). 
LOD 
LOD  0,31 
0,002 
0,66 Median  
Median 
0,75 
0,34 
Highest category 
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The differences in urinary cadmium concentrations between the studies could be 
attributed to a real difference in exposure with a higher long-term body accumulation of 
cadmium in women in Lund (Southern Sweden) than in Uppsala (lower part of Central 
Sweden). On the other hand, alternative explanations could at least in part contribute to 
the observed differences. The women in the SMC were somewhat older than the 
women in the WHILA study, thus it cannot be excluded that an age-related decline in 
kidney cadmium accumulation [84], eventually resulting in slightly lower urinary 
cadmium excretion, has occurred. Moreover, the LOD was substantially lower in the 
SMC (0.002 µg/L; first black line in Figure 6) than in the WHILA study (0.31 µg/L; 
first grey line in Figure 6), and polyatomic interferences of molybdenum oxide were 
only removed in the cadmium analyses in SMC. Thus, analytical differences may also 
contribute to the observed differences.  
 
The mean urinary cadmium concentration in SMC is similar to that observed in men 
from an area in Eastern Sweden considered to be environmentally contaminated [57, 
97]; while the mean urinary cadmium concentration in the WHILA study is similar to 
that of the women in the same study [57, 97]. The concentrations are, however, lower 
in both SMC and WHILA than those observed in Belgium [55], USA (NHANES) [63], 
and much lower than those in Japan [42]. However, as urinary cadmium also depends 
on sex, age and smoking habits, these aggregated data-comparisons are not always 
meaningful.  
 
Among never-smokers, the urinary cadmium concentrations were, as expected; lower 
than among all women (Figure 7), due to the inclusion of smokers among all women. 
The median cadmium concentration in never-smoking women in the SMC was 0.29 
µg/g creatinine and in the WHILA study 0.55 µg/g creatinine (p<0.001 for difference). 
In the WHILA study, 32% of never-smoking women had cadmium concentrations 
>0.50 µg/g as compared to 6% in the SMC.  
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Figure 7. Comparison of urinary cadmium (µg/g creatinine) in the SMC and WHILA study 
among never-smoking women.  
 
Blood cadmium was only measured in the WHILA study (Paper III). The median 
blood cadmium concentration was 0.38 µg/L among all women and 0.31 µg/L among 
never-smoking women, which is similar to that observed in Swedish twins (aged 49 to 
92 years; mean 68 years) [98] and in women in Southern Sweden (50-59 years) [99], 
but higher than in Northern Sweden [99, 100]. The blood cadmium concentrations 
among never-smoking women were also similar to those found in younger women as 
well as in women in the same age range in Western and Southern Sweden [39, 40] and 
in Norway [101]. The concentration of cadmium in blood and urine were correlated; 
rp=0.55; p<0.001 (n=593).  
 
5.1.2 Dietary cadmium intake 
The mean estimated dietary cadmium intake via the FFQ was 13 µg/day (range 3-29 
µg/day) (Paper II), which is in the same range as those observed in Europe and USA 
(average between 8 and 25 µg/day) [39, 40, 102-108]. The EFSA set a tolerable weekly 
intake (TWI) of 2.5 µg cadmium/kg body weight to avoid cadmium-induced kidney 
effects in the general population [6]. In this study (Paper II), the estimated average 
0,55 
Median 
Median 
0,29 
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intake was 1.4 day (range 0.36-3.6) µg cadmium/kg body weight and week, and only 
0.7% of the women exceeded the TWI.   
 
5.2 CADMIUM AND BONE 
5.2.1 Cadmium and BMD 
In Paper I and II (SMC), we measured BMD at the total body, femoral neck, total hip 
and lumbar spine (L2-L4). Several covariates were significantly associated with BMD. 
The most pronounced associations involving all BMD sites were those for age, height, 
total fat mass, lean body mass, and use of postmenopausal hormones (p≤0.001). Thus, 
BMD decrease with age and increase with height, total fat mass, lean body mass and 
use of postmenopausal hormones (p≤0.002 for all).  
 
Urinary cadmium (as a continuous variable) was in the crude analyses as well as after 
multivariable-adjustments significantly inversely associated with BMD at all the sites 
measured (Figure 8). The only exception was the association with BMD at the lumbar 
spine, which after multivariable-adjustment fell out of statistical significance (p=0.088). 
Although no women had spondylosis at the lumbar spine, which may result in falsely 
elevated BMD attenuating the observed associations, the general variability of BMD at 
the lumbar spine was to some extent higher (mean ± SD; 1.13±0.18 g/cm2) than that at 
the femoral neck (0.89±0.12 g/cm2) and total hip (0.94±0.12 g/cm2) in accordance with 
studies in twins [109]. The higher variability may explain the somewhat weaker 
multivariable-adjusted association and lower explained variance (14%) in the analysis 
of BMD at the lumbar spine, as compared to the hip.  
 
Our study is the first to ever assess the associations between urinary cadmium and 
BMD at the total body, and the first to assess the association with BMD at the lumbar 
spine in the general population. Only two previous studies (in occupationally exposed 
men) have assessed the association between urinary cadmium and BMD at the lumbar 
spine [110, 111]. Järup and colleagues however reported null associations (n=43) [110], 
while Nawrot and colleagues observed a non-significant inverse association (p=0.14; 
n=83) [111].  
 
Our results (Paper I) are in line with the inverse associations observed between urinary 
cadmium and BMD in previous studies [55, 57, 60, 61, 63]. However, it should be 
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noted that all these studies, with the exception of the NHANES-study [63], restricted 
the BMD measurement to the forearm.  
 
In Paper I, the strongest correlation was observed at the total body, followed by total 
hip (Figure 8). Interestingly, both the age-adjusted as well as the multivariable-adjusted 
regression coefficients for urinary cadmium were fairly similar between the different 
sites measured, supporting the consistency of our findings.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. The association between urinary cadmium and BMD at the different sites expressed 
as crude (Spearman rank correlation coefficient; rs), age-adjusted regression coefficients (B1) 
and multivariable-adjusted regression coefficients (B2).  B2 was adjusted for age, education, 
height, total fat mass, lean body mass, parity, ever use of postmenopausal hormones, ever use of 
corticosteroids, physical activity, alcohol intake, smoking, inflammatory joint diseases, kidney 
diseases, liver diseases, and malabsorption. Figure: Magga-Rita. 
 
   
The most pronounced inverse association (lowest regression coefficient, B2= − 0.031) 
between urinary cadmium and BMD was observed at the total hip, with a higher 
content of cortical bone as compared to the femoral neck (B2= − 0.023). This may 
indicate that cortical bone could be more affected than trabecular bone. The NHANES 
study, based on women 50 to 90 years of age, is the only previous study performed in 
Lumbar spine L2-L4 
Paper I:  
rs= -0.052,  p=0.007 
B1= -0.043, p=0.011, Adj. R2=0.005 
B2= -0.028, p=0.088, Adj. R2=0.14  
Total hip 
Paper I:  
rs= -0.068, p<0.001 
B1= -0.050, p<0.001, Adj. R2=0.027 
B2= -0.031, p=0.004, Adj. R2=0.18 Total body 
Paper I: 
rs= -0.088, p<0.001 
B1= -0.044, p<0.001, Adj. R2=0.038 
B2= -0.027, p<0.001, Adj. R2=0.23 
 
Femoral neck 
Paper I: 
rs= -0.057, p=0.003 
B1= -0.038, p<0.001, Adj. R2=0.038 
B2= -0.023, p=0.025, Adj. R2=0.17 
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the general population that has measured BMD at the femoral neck and total hip in 
relation to cadmium exposure [63]. In line with the result in the present study (Paper 
I), the NHANES study observed inverse associations between urinary cadmium and 
BMD at these two sites with some slight indication of stronger inverse association at 
the total hip than at the femoral neck [63]. Similarly, Nawrot et al, demonstrated a more 
pronounced inverse association at the total hip than at the femoral neck in 
occupationally exposed men (p=0.03 and p=0.11, respectively) [65]. However, also 
sites including higher content of trabecular bone showed inverse associations with bone 
(Figure 8). Involvement of both bone tissues is supported by animal studies (see e.g. 
[70, 112-116]. Cadmium enhanced the stiffness in cortical bone and decreased the 
elasticity in trabecular bone, making the bone more prone to fractures [115]. Female 
animals seem to be more vulnerable to cadmiums effect on bone than male ones [70]. 
Aging itself makes the bone stiffer and less elastic [117, 118].  
 
There was no indication of a non-linear association between urinary cadmium and 
BMD at the total body (Figure 9); as also was the case at the femoral neck, total hip 
and lumbar spine. However, in order to understand if the effect varied at different 
exposure levels, we also assessed the associations with BMD using categorized urinary 
cadmium (Table 2 and Figure 10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Multivariable-adjusted BMD at the total body. Vertical  lines display the cutoffs for 
the different exposure categories (<0.50, 0.50-0.75 and ≥0.75 µg/g creatinine) used in Paper I.  
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Table 2 and Figure 10 show the associations between categorized urinary cadmium 
and BMD at the various sites (results not presented in Paper I). The highest exposure 
category (≥0.75 µg/g creatinine) was significantly inversely associated with BMD at all 
sites, while the second highest exposure category (0.50-0.75 µg/g creatinine) was 
significantly associated with BMD at the total body and lumbar spine and borderline 
significant at the total hip. The results were consistent when using tertiles of urinary 
cadmium, instead of the chosen cutoffs, supporting the robustness and consistency of 
our findings.  
 
 
Table 2. Multiple linear regression coefficients and their 95% confidence intervals (CI) of 
categorized urinary cadmium in relation to BMD (g/cm2) at the total body, femoral neck, total 
hip and lumbar spine. 
BMD  Regression coefficient (95% CI) p-value Adjusted R2 
Total body (TB)     
Urinary cadmium <0.50 Reference - 0.23 
(µg/g creatinine) a 0.50-0.75 -0.013 (-0.021; -0.0044) 0.003  
 ≥0.75 -0.027 (-0.039; -0.014) <0.001  
     
Femoral neck (FN)     
Urinary cadmium <0.50 Reference - 0.17 
(µg/g creatinine) a 0.50-0.75 -0.009 (-0.020; +0.0023) 0.12  
 ≥0.75 -0.032 (-0.049; -0.015) <0.001  
     
Total hip (TH)     
Urinary cadmium <0.50 Reference - 0.18 
(µg/g creatinine) a 0.50-0.75 -0.012 (-0.023; +0.0010) 0.052  
 ≥0.75 -0.042 (-0.059; -0.024) <0.001  
     
Lumbar spine (LS)     
Urinary cadmium <0.50 Reference - 0.14 
(µg/g creatinine) a 0.50-0.75 -0.019 (-0.037; -0.00097) 0.039  
 ≥0.75 -0.031 (-0.058; -0.0041) 0.024  
a Multivariable-adjusted for age, education, height, total fat mass, lean body mass, parity, use of 
postmenopausal hormones, ever use of corticosteroids, total physical activity, smoking status, alcohol 
intake, inflammatory joint diseases, kidney diseases, liver diseases, malabsorption. 
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Figure 10. Multiple linear regression coefficients and 95% CI of categorized urinary cadmium 
in relation to BMD (g/cm2) at the total body (TB), the femoral neck (FN), the total hip (TH) 
and the lumbar spine (LS). 
 
 
 
Based on categorized multivariable-adjusted urinary cadmium, we estimated the 
magnitude of difference in BMD between the lowest and the highest exposure groups. 
As shown in Figure 11A, the adjusted mean BMD was lowest in the highest exposure 
category. The magnitude of the difference in BMD, moving from the lowest urinary 
cadmium category (<0.50 µg/g creatinine) to the highest (≥0.75 µg/g creatinine), was 
similar to that observed for a 5-11 years increase in age (for further details, see Paper 
I). This suggests that the cadmium-associated differences observed in BMD are 
relevant in a clinical perspective. The adjusted mean of BMD for never-smoking 
women are shown in Figure 11B. 
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Figure 11. Adjusted mean of BMD based on categorized urinary cadmium among all women 
and never-smoking women (Paper I). 
 
 
In the general non-smoking population, the diet is the most important source of 
cadmium exposure [6, 42]. Paper II is the first study to assess the associations between 
estimated dietary cadmium intake and BMD. After multivariable-adjustment, dietary 
cadmium intake was inversely associated with BMD at the total body and lumbar spine, 
but not with BMD at the femoral neck. Interestingly, after further adjustments for 
dietary factors known to be important for bone health (i.e. calcium, magnesium and 
iron) [119], and for cadmium bioavailability (i.e. iron and fiber), the associations 
became more pronounced, also at the femoral neck (Table 3). This may indicate that 
there exists a possible risk-benefit association between the dietary exposure of 
cadmium and the consumption of food considered healthy with a high content of 
calcium, magnesium, iron and fiber. A risk-benefit relationship has previously been 
demonstrated for fruit and vegetable consumption in the association between dietary 
cadmium intake and risk of fractures [107].  
a 
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We performed sub-group analyses restricted to never-smokers in order to explore 
whether tobacco smoking confounded our results. However, this restriction did not 
attenuate our associations, indicating that the associations were attributable to dietary 
cadmium intake alone (Table 3, see below).  
 
 
As observed in Figure 12 (Paper II), almost identical multivariable-adjusted linear 
associations were observed for urinary cadmium as for dietary cadmium exposure in 
relation to BMD at the total body. This finding provides important support for the 
utility of questionnaire-based estimated dietary cadmium exposure in large-scale 
epidemiological studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.Multivariable-adjusted linear regression for dietary cadmium intake (per 10 µg/day-
increment) (grey) and for urinary cadmium (per 1 µg/g creatinine-increment) (black) in relation 
to total-body BMD. 
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Table 3. Multiple linear regression based on continuous (per 10 µg/day-increment) dietary cadmium intake and 95% CI in relation to BMD 
(g/cm2) at the total body, femoral neck and lumbar spine in all women and in the subgroup of never-smokers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adj R2: Adjusted variance for the total model 
a
 Age-adjusted estimate for dietary cadmium intake 
b
 Multivariable-adjusted for age (years), education (≤9 and >9 years; yes/no), body mass index (kg/m2), ever use of postmenopausal 
hormones (yes/no), total physical activity (MET-hours/day), smoking status (never/ever), alcohol intake (g ethanol/day), inflammatory 
joint diseases (yes/no) 
c
 Multivariable-adjusted model, additionally adjusted for dietary intake of calcium (mg/day), magnesium (mg/day), iron (mg/day), fiber 
(g/day)  
 Bone mineral density   
 All women, n=2676   Never-smokers, n=1220   
 Regression coefficient (95% CI) p-value Adj R2  Regression coefficient (95% CI) p-value Adj R2 
Total body       
 Dietary cadmiuma -0.008 (-0.020 to +0.005) 0.25 0.03 -0.011 (-0.031 to +0.008) 0.26 0.02 
 Dietary cadmiumb -0.012 (-0.024 to -0.00026) 0.045 0.16 -0.020 (-0.038 to -0.001) 0.036 0.14 
 Dietary cadmiumc -0.021 (-0.038 to -0.005) 0.01 0.16 -0.026 (-0.052 to -0.001) 0.04 0.14 
Femoral neck       
 Dietary cadmiuma 0.001 (-0.016 to +0.017) 0.94 0.034 -0.004 (-0.029 to +0.022) 0.78 0.02 
 Dietary cadmiumb -0.001 (-0.017 to +0.015) 0.89 0.12 -0.009 (-0.033 to +0.016) 0.49 0.09 
 Dietary cadmiumc -0.018 (-0.040 to +0.004) 0.11 0.12 -0.021 (-0.054 to +0.013) 0.22 0.09 
 Lumbar spine       
 Dietary cadmiuma -0.031 (-0.058 to-0.005) 0.02 0.004 -0.041 (-0.081 to -0.001) 0.044 0.003 
 Dietary cadmiumb -0.038 (-0.063 to -0.012) 0.004 0.1 -0.054 (-0.093 to -0.015) 0.003 0.09 
 Dietary cadmiumc -0.058 (-0.093 to -0.023) 0.001 0.1 -0.068 (-0.12 to -0.014) 0.013 0.08 
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In additional analyses we assessed the combined effect of having high dietary and high 
urinary cadmium. As tobacco smoking may confound these analyses, we also 
performed separate analyses among never-smokers. In this combined analysis the 
inverse association between exposure and BMD at all sites was even more pronounced 
(Figure 13), as compared to the separate analyses (Paper I and II). As there were no 
differences in dietary or urinary cadmium in the different exposure categories between 
the separate and combined analyses (Table 4), the result indicate an underestimation of 
the association between cadmium and bone in the separate analyses. Thus, each of the 
single markers underestimated the risk indicating some exposure misclassification. The 
regression coefficients were slightly stronger in the sub-group of never-smokers as 
compared to those observed in all women (Figure 13), indicating that the lower BMD 
was attributed to cadmium from non-tobacco sources (i.e. mainly food).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Multivariable-adjusted linear coefficient and 95% CI of BMD in relation to 
combined high dietary cadmium (≥13 µg/day), and high urinary cadmium (≥0.50 µg/g 
creatinine) as compared to the reference categories (          ) of low dietary (<13 µg/day) and 
low urinary cadmium (<0.50 µg/g creatinine) among all women (       ) and among never-
smoking women (      ). The model was adjusted for age, education, body mass index, ever use 
of postmenopausal hormones, total physical activity, smoking status, alcohol intake, 
inflammatory joint diseases, and dietary intake of calcium, magnesium, iron, and fiber.  
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Table 4. Mean and median urinary and dietary cadmium in each category (<0.50 and ≥0.50 
µg/g creatinine; <13 and ≥13 µg/day), respectively and in the combined analyses. 
 Categories Mean Median 
Urinary cadmium 
(µg/g creatinine)      
<0.50 
 
0.28 0.27 
 ≥0.50 0.65 0.60 
Dietary cadmium 
(µg/day)                 
<13 11 11 
 ≥13 15 15 
  Urinary 
cadmium 
Dietary 
cadmium 
Urinary 
cadmium 
Dietary 
cadmium 
Low category  
 
<0.50 and <13 0.28 11 0.27 11 
Intermediate category 
 
 
<0.50 and <13;  
≥0.50 and ≥13 
0.32 14 0.29 14 
High category    ≥0.50 and ≥13 0.66 15 0.60 14 
 
A certain degree of misclassification of the women’s long-term dietary cadmium 
exposure is not surprising as measurement error is inevitable due to it being based on 
self-report, dietary information in combination with the average cadmium 
concentration in each food item reported. By excluding women with implausible 
energy intake and by adjusting cadmium to the total caloric intake, under- or over 
reporting of habitual food intake is compensated for. However, as cadmium is not an 
intrinsic part of food the variation might be larger than for nutrients. Also the 
bioavailability of cadmium in food may differ substantially depending on both dietary 
factors and nutritional status, and that may lead to exposure misclassification in relation 
to the internal dose. For example, dietary cadmium may be less bioavailable in a high-
fiber diet than in a low fiber-diet [40]. On the other hand, fermented fiber may increase 
e.g. the calcium uptake and thus increase the BMD [120, 121]. By adjusting our models 
by intake of dietary fiber, and calcium and magnesium some compensation of these 
variations seemed to be obtained. However, the most important factor for the 
bioavailability of cadmium in the diet seems to be the iron status of the individual. Low 
iron stores are associated with higher concentrations of cadmium in blood, urine and 
kidneys, as shown in several different populations [39, 40, 43, 45, 101, 122]. The likely 
explanation is the increased gastrointestinal uptake of cadmium via the apical divalent 
metal transporter 1 (DMT1) and the basolateral ferroportin 1 (FPN1) [123-126] in the 
enterocytes at iron deficiency. Low body iron stores and iron deficiency are common in 
premenopausal women due to menstrual losses and to pregnancy [127]. Unfortunately, 
for these Papers (Paper II), we did not have any information on the women’s body iron 
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stores earlier in life. Although there is little evidence that the iron intake per se is 
related to the body iron stores, the association between dietary cadmium and bone was 
more pronounced after adjustment by dietary iron, supporting some confounding by 
this nutrient. Taking all these aggravating factors into consideration, it is indeed 
remarkable that an inverse association could be observed between the estimated dietary 
cadmium intake and bone.  
 
More surprising, is that also the use of urinary cadmium alone led to underestimation of 
the risk (Table 2, 6, 8; Figure 10, 14-17), in turn indicating some exposure 
misclassification also by using urinary cadmium as a marker of long-term exposure. 
Cadmium in urine is considered to mainly reflect the kidney accumulation [6, 49] and 
thus the long-term integrated exposure from all sources, including non-dietary sources. 
Urinary cadmium concentrations increase with age but may decline due to aging [84]. 
We used an age cut-off <70 years in Paper I and II to avoid this exposure 
misclassification. However, we cannot exclude that the age (up to 69 years) has 
introduced some exposure misclassification, although there was no indication of this in 
the correlation between urinary cadmium and age (rs=0.029, p=0.13; not shown in 
Paper I and II). Inter-individual variation in the toxicokinetics of cadmium and kidney 
physiology [38] as well as the method used to compensate for variation in urine dilution 
[128, 129] may affect how well urinary cadmium reflect the long-term exposure. In any 
case, by combining urinary cadmium with measurements of dietary cadmium intake, it 
seems as if the level of misclassification can be reduced.  
 
5.2.2 Cadmium and osteoporosis  
We also estimated the risk of osteoporosis in relation to cadmium exposure at sites 
particular susceptible to osteoporotic fractures (Paper I and II). Osteoporosis was 
defined as T-score <-2.5 which approximately corresponded to a cutoff in BMD of 0.70 
g/cm2 at the femoral neck, 0.67 g/cm2 at the total hip, and 0.90 g/cm2 at the lumbar 
spine. As expected, age was positively associated with the risk of osteoporosis at all 
sites (p<0.001); the mean age of women with osteoporosis was 65 years as compared to 
64 years in those without osteoporosis.  
 
The prevalence of osteoporosis was 8 and 10% at the femoral neck and lumbar spine, 
respectively and 15% when considering osteoporosis at either the femoral neck or 
lumbar spine (Table 5). This prevalence is only slightly lower than the 10% observed 
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at the femoral neck in 56 to 59 year old, the 14% observed in 60 to 64 year old and 
20% in 65 to 69 year old women in Sweden [11], indicating that the women included in 
Paper I and II is fairly representative of Swedish women of similar age.  
 
Women with osteoporosis had higher urinary cadmium concentrations and a slightly 
higher dietary cadmium intake than without osteoporosis (Table 5).  
 
 
Table 5. The prevalence of osteoporosis (OP) and the median concentrations of urinary 
cadmium (µg/g creatinine) and dietary cadmium (µg/day) in women with or without 
osteoporosis.  
Site T-score, <-2.5;  
n of women (%) with 
osteoporosis 
Urinary  
cadmium  
OP vs no OP  
Dietary 
cadmium#  
OP vs no OP 
Paper  
Femoral neck 216 (8.2%) 0.43 vs 0.34  - I 
Total hip 55 (2.1%) 0.43 vs 0.34  - I 
Lumbar spine 267 (10%) 0.38 vs 0.34  - I 
Hip or spine 400 (15%) 0.39 vs 0.34  12.9 vs 12.6  I and II 
#
 Restricted to hip or spine to increase the statistical power. 
 
 
In line with the results for BMD, we found significantly positive associations between 
urinary cadmium as a continuous variable, rescaled to 0.42 µg/g creatinine (equivalent 
to 2 SD) and risk of osteoporosis at the femoral neck, total hip, lumbar spine, and hip or 
spine (Paper I). The increased risk estimated per 2 SD-increment varied between 
40% and 60% at the different sites. For categorized urinary cadmium, the highest 
exposure group (≥0.75µg/g creatinine) compared with the lowest (<0.50 µg/g 
creatinine) was associated with 2- to 3-fold increased risk of osteoporosis at all three 
sites. For femoral neck and hip or spine, also the second highest urinary cadmium 
exposure group (0.50 to 0.75 µg/g creatinine) was associated with higher risk of 
osteoporosis. To enable comparison with previous studies, we also calculated the risk 
of osteoporosis per µg/g creatinine in urinary cadmium (Table 6; data not shown in 
Paper I, except for total hip).  
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Table 6. Risk of osteoporosis and its 95% CI at the femoral neck, total hip, lumbar spine and 
hip or spine based on continuous urinary cadmium (per 1 µg/g creatinine increment) among 
all women and in the subgroup of never-smokers.  
 Odds ratioa (95% CI) 
Site All women Never-smokers 
Femoral neck 2.97 (1.61-5.52) 4.90 (1.57-15.5) 
Total hipb 3.11 (1.23-7.88) Numbers too small to perform analyses 
Lumbar spine 2.27 (1.25-4.11) 2.04 (0.70-5.98) 
Hip or spine 2.34 (1.39-3.95) 2.84 (1.12-7.19) 
a Multivariable-adjusted for age, education, height, total fat mass, lean body mass, parity, use of 
postmenopausal hormones, ever use of corticosteroids, total physical activity, smoking status, alcohol 
intake, inflammatory joint diseases, kidney diseases, liver diseases, malabsorption. 
b
 Model only adjusted for significant covariates (age, height, total fat mass, lean body mass and ever 
use of corticosteroids) because Hosmer-Lemeshow test indicated instability when all covariates were 
included.  
 
 
 
In separate analyses among never-smokers the multivariable-adjusted OR for 
osteoporosis was 1.95 (95% CI 1.21–3.16) at the femoral neck and 1.55 (95% CI 1.05–
2.29) at the hip or spine for every 0.42 µg/g of creatinine (=2 SD) increment in urinary 
cadmium (Paper I). The highest exposure category of urinary cadmium (≥0.75 µg/g of 
creatinine) was associated with a 3- to 4-fold significantly increased risk of osteoporosis 
at the femoral neck, lumbar spine, and hip or spine. Thus, the association between 
urinary cadmium and risk of osteoporosis tended to be more pronounced among never-
smoker than among all women. The reason for this difference is not known, but the 
women not classified as never-smokers were more heterogeneous both with respect to 
cadmium exposure and bone health. This group of women consists of both current and 
former smokers with a wide variety in the amount of cigarettes smoked. Smoking 
cessation is associated with a beneficial effect on bone and is often accompanied with 
an increase in body weight (also beneficial for bone), while the urinary cadmium 
concentrations may remain essentially the same. Altogether this may increase the total 
variation, attenuating the associations in all women. It can only be speculated that 
inhaled cadmium have a different toxic effect on bone than the cadmium absorbed via 
the diet. We found similar associations between dietary cadmium exposure and 
increased risk of osteoporosis at the hip or spine, as for urinary cadmium, although not 
as clear. 
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Per 10 µg/day-increment of dietary cadmium, we observed OR = 1.46 (95% CI: 0.97-
2.20) (Paper II). By further adjustment for dietary calcium, magnesium, iron and fiber, 
we observed a significantly increased risk of osteoporosis, OR, 1.97 (95% CI: 1.12-
3.48). The high dietary cadmium exposure category (≥13 µg/d = the median) as 
compared to the low (<13µg/d) was associated with a 32% significantly increased risk 
of osteoporosis (OR, 1.32 (95% CI, 1.02-1.71)) (Figure 14B). Among never-smoking 
women, a 34% increased risk was observed comparing high with low, but this was not 
statistically significant (OR, 1.34, 95% CI, 0-93-1.95) (Figure 15B). In the combined 
analysis, again the risk of osteoporosis was considerably higher than in the separate 
analyses, OR 2.49 (95% CI; 1.71-3.63) (Figure 14C) among all women and OR 2.65 
(95% CI; 1.43-4.91) among never-smoking, respectively (Figure 15C). Results for 
urinary cadmium are given for comparison (Figure 14A and 15A).  
 
Figure 14. Multivariable-adjusted odds ratio and 95% CI of osteoporosis at the hip or spine 
among all women. Urinary cadmium (A) as categorized into below (low) or above (high) 0.50 
µg/g creatinine; estimated dietary cadmium (B) as categorized into below (low) or above (high) 
the median, 13 µg/day and (C) with combined high urinary cadmium (≥0.50 µg/g creatinine) 
and dietary cadmium (≥13 µg/day), as compared to the reference category (<0.50 µg/g 
creatinine and <13 µg/day). For covariates; see Paper I and II. 
All women 
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Figure 15. Multivariable-adjusted odds ratio and 95% CI of osteoporosis at the hip or spine 
among never-smoking women. Urinary cadmium (A) as categorized into below (low) or above 
(high) 0.50 µg/g creatinine; estimated dietary cadmium (B) as categorized into below (low) or 
above (high) the median, 13 µg/day and (C) with combined high urinary cadmium (≥0.50 µg/g 
creatinine) and dietary cadmium (≥13 µg/day), as compared to the reference category (<0.50 
µg/g creatinine and <13 µg/day). For covariates; see Paper I and II. 
 
 
 
As shown in Table 4 (page 50), the more pronounced association observed after 
combining dietary with urinary cadmium (Figure 13, 14C, and 15C) was not due to 
unintentionally higher exposure in the high exposure category.  
 
5.2.3 Cadmium and fractures 
Besides BMD and the risk of osteoporosis, we also evaluated the risk of fractures 
(ascertained from 1997 to 2009) in relation to cadmium (Paper I and II). The number 
of fractures is shown in Table 7. As expected, a fracture at the distal forearm was the 
most common fracture in women (Paper I). Given the limited number of fractures, we 
used only two categories of cadmium exposure. The concentration of cadmium in urine 
was slightly higher among women with fractures than without (Table 7). 
A B C 
Never-smoking women 
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Table 7. Total number and percent (%) of any first incident fracture, first osteoporotic fracture 
and the most common first fracture (distal forearm) among all women. The mean urinary 
cadmium concentration (µg/g creatinine) and the estimated dietary cadmium intake (µg/day) 
are compared between women with or without a fracture.  
a
 Includes fractures of the hip, spine, distal forearm, proximal humerus, and pelvis. 
 
In the analysis of any first incident fracture we observed per 0.42 µg/g creatinine (=2 
SD) increment in urinary cadmium, a multivariable adjusted OR of 1.15 (95% CI, 0.92-
1.43) among all women and a borderline statistically significant higher risk, OR 1.48 
(95% CI, 1.00-2.17), among never-smokers. For categorized urinary cadmium, the 
higher risk of fractures among all women was also non-significant, OR, 1.16 (95% CI, 
0.89-1.50) while a clearly statistically significantly higher risk was observed among 
never-smokers OR, 2.03 (95% CI, 1.33-3.09) comparing urinary cadmium ≥0.50 µg/g 
creatinine with lower levels). Similar results were observed in the analysis of any first 
osteoporotic fracture and first fracture of the distal forearm (Paper I).  
To enable comparison with previous studies, we calculated the risk of fracture per 1 
µg/g creatinine of urinary cadmium (Table 8; data not shown in Paper I).  
 
Table 8. Multivariable-adjusted risks per 1 µg/g creatinine and its 95% CI of any first 
fracture, first osteoporotic fracture, and first distal forearm fracture, among all women and in 
the subgroup of never-smokers. 
 Odds ratioa (95% CI) 
 All women Never-smokers 
Any first fracture 1.39 (0.82-2.34) 2.54 (1.00-6.33) 
First osteoporotic fractureb 1.12 (0.57-2.15) 3.25 (1.15-9.29) 
Most common first fracture;  
distal forearm 
1.57 (0.70-3.64) 6.12 (1.80-21.1) 
a 
 Multivariable-adjusted for age, education, height, total fat mass, lean body mass, parity, use of 
postmenopausal hormones, ever use of corticosteroids, total physical activity, smoking status, alcohol 
intake, inflammatory joint diseases, kidney diseases, liver diseases, malabsorption. 
 Fractures,  
n (%)  
Urinary  
cadmium  
 Fracture  vs 
no fracture 
Dietary 
cadmium  
Fracture  vs 
no fracture 
Paper  
Any first fracture 395 (15%) 
 
0.43  vs 0.34 
 
13.0 vs12.6  
 
I and II  
First osteoporotic 
fracturea 
248 (9.2%) 0.43 vs.034  
 
- I 
Most common first 
fracture; distal forearm 
137 (5.1%) 0.38 vs 0.34  
 
- I 
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It is well-known that low BMD explains a major part of the risk of fracture [11]. Thus, 
in additional analysis we explored whether the cadmium-related risk of fractures was 
mediated via lowered bone mass. Inclusion of total body BMD in the fracture models 
did, however, only partly remove the higher risks (Table 5; Paper I), indicating that 
cadmium exposure may result in other effects on bone that are not detected by DXA.  
 
We also explored the risk of any first incident fracture in relation to dietary cadmium 
(Paper II). Per 10 µg/day-increment of dietary cadmium, we observed a non-
statistically significant OR, 1.14 (95% CI: 0.76-1.71), which after further adjustment for 
the dietary intake of calcium, magnesium, iron, and fiber was OR = 1.44 (95% CI: 0.82-
2.53) (Paper II). Women with a cadmium intake above the median, compared to values 
below median had an OR of 1.31 (95% CI: 1.02-1.69) and the corresponding OR among 
never-smokers was 1.54 (95% CI: 1.06-2.24) (Figure 16B). Results for urinary 
cadmium are given for comparison (Figure 16A and 17A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Multivariable-adjusted odds ratio and 95% CI of any first incident fracture among 
all women. Urinary cadmium (A) as categorized into below (low) or above (high) 0.50 µg/g 
creatinine; estimated dietary cadmium (B) as categorized into below (low) or above (high) the 
median, 13 µg/day and (C) with combined high urinary cadmium (≥0.50 µg/g creatinine) and 
dietary cadmium (≥13 µg/day), as compared to the reference category (<0.50 µg/g creatinine 
and <13 µg/day). For covariates; see Paper I and II. 
All women 
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Figure 17. Multivariable-adjusted odds ratio and 95% CI of any first incident fracture among 
never-smoking women. Urinary cadmium (A) as categorized into below (low) or above (high) 
0.50 µg/g creatinine; estimated dietary cadmium (B) as categorized into below (low) or above 
(high) the median, 13 µg/day and (C) with combined high urinary cadmium (≥0.50 µg/g 
creatinine) and dietary cadmium (≥13 µg/day), as compared to the reference category (<0.50 
µg/g creatinine and <13 µg/day). For covariates; see Paper I and II. 
 
 
As observed in the analyses for BMD and risk of osteoporosis, the combined analyses 
of high urinary and high dietary cadmium also revealed more pronounced associations 
with fractures. The corresponding results for risk of any first incident fracture were OR, 
1.46 (95% CI: 1.00-2.15) among all women and OR, 3.05 (95% CI: 1.66-5.59) among 
never-smokers, respectively (Figure 16C and 17C).  
 
 
Besides Paper I and II, only three studies have so far considered fracture incidence 
either using urinary cadmium or estimated dietary cadmium as the exposure marker. 
The two studies based on urinary cadmium were performed in both women and men in 
industrially contaminated areas in Belgium [55] and in Sweden [58]. The study based 
on dietary cadmium exposure (using the same database of cadmium content in food as 
in the present study) assessed fracture incidence in men in an area with no known 
industrial contamination [107]. In the study from Belgium, a two-fold increase of 
Never-smoking women 
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urinary cadmium excretion was associated with a higher risk of any fracture in women; 
risk ratio (RR) 1.73 (95% CI, 1.16-2.57) but not in men. Cadmium was also analyzed in 
soil, leek and celery, sampled from the residence of the subjects, and was used as proxy 
of cadmium exposure. A similar risk estimate was observed as when using the urinary 
cadmium concentrations. The women in the study by Staessen and colleagues [55], had 
about twice the cadmium concentrations in urine as observed in the women in the 
present study (Paper I). Alfvén and colleagues [58] reported, per 1 nmol/mmol 
creatinine a hazard ratio (HR) of 1.18 (95% CI, 1.01–1.37) for forearm fracture in 
subjects over 50 years of age. Thomas et al [107] assessed the association between 
estimated dietary cadmium intake, comparing the highest with the lowest tertile. The 
risk of any first incident fractures was HR of 1.19 (95% CI, 1.06-1.34) as well as first 
incident hip fracture was HR 1.28 (95% CI, 0.97-1.69) in men from Sweden. In 
accordance with the findings in the present study (Paper II), the observed adverse 
associations between dietary cadmium intake and fractures were partly masked by 
dietary factors (i.e. fruits and vegetables).  
 
The study by Thomas et al [107] is, besides Paper I and II the only to have evaluated 
the risk of fractures separately in never-smokers. In accordance with Paper II, the 
risk of hip fractures was more pronounced in never-smokers as compared to all men, 
HR, 1.70 (95% CI, 1.04-2.77) as compared to all men including smokers HR, 1.28 
(95% CI, 0.97-1.69).  
 
 
In conclusion, our results indicate that cadmium is a risk factor for osteoporosis and 
fractures. As the risk was generally more pronounced among never-smokers than 
among all women, it seems obvious that cadmium from the diet alone contributes to 
lower BMD, and increased risk of osteoporosis and fractures. The risk occurred at 
lower cadmium concentrations than previously observed, starting already at 0.50 µg/g 
creatinine, indicating larger concern than previously known. Because the high 
incidence of fractures is of major public health concern due to the reduced quality of 
life, reduced life expectancy and high costs for society associated with the disease, 
the results are of public health concern.  
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5.3 VITAMIN D, CADMIUM AND BONE 
In Paper III, we assessed 1,25(OH)2D in serum, selected on the basis of the lowest 
(n=45) and highest (n=40) urinary cadmium concentrations in WHILA. The median 
concentration of urinary cadmium in the low group was 0.25 µg/L (5-95th percentile; 
0.14-0.39 µg/L), as compared to 1 µg/L (0.66-2.1 µg/L) in the high cadmium group. 
The corresponding urinary cadmium concentration adjusted for creatinine was 0.36 
µg/g creatinine and 1.1 µg/g creatinine, respectively. A similar exposure contrast was 
observed in blood. The concentration of 1,25(OH)2D in all samples was 114 pmol/L (5-
95th percentile; 67-171 pmol/L; n=85). The median concentration of 25(OH)D was 102 
nmol/L (n=42), which is somewhat higher than previously observed in Swedish women 
and men [130-132]. The ratio between 1,25(OH)2D and 25(OH)D was approximately 
1:1000.  
 
The women in the high-cadmium group had also significantly higher concentrations of 
markers of tubular damage and bone resorption, and a lower BMD and estimated lower 
glomerular filtration rate, as compared to the women in the low-cadmium group. This is 
in line with the results on cadmium-associated effects on both bone and kidney, 
previously reported in these women (n=820) [53, 61], and indicates a sufficient sample 
size. There was also a higher prevalence of women smoking in the high group, as 
compared to the low group. However, we found no statistically significant difference in 
serum 1,25(OH)2D concentrations between the two urinary cadmium exposure groups. 
If anything, there was a tendency of a higher concentration of serum 1,25(OH)2D in the 
high exposure group as compared to the low cadmium group (p=0.08). Furthermore, 
inclusion of  25(OH)D measurements in a subsample of the women, reduced the 
possibility that our null results were biased due to differences in vitamin D status.  
 
In the final multivariable-adjusted model, only urinary calcium, besides either urinary 
or blood cadmium was included and, again, only urinary calcium, and not cadmium 
was significantly positively associated with 1,25(OH)2D. Thus, we interpret that the 
activation of 1,25(OH)2D, that mainly takes place in the kidneys was not affected by 
cadmium in these women. However, it cannot be completely ruled out that a 
compensatory slower degradation of 1,25(OH)2D or increased activation of 
1,25(OH)2D in other tissues may have occurred [133] that could mask a possibly lower 
cadmium-induced activation in the kidney. In accordance with our results, some 
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experimental studies have observed no difference in 1,25(OH)2D levels [134-136], or 
even higher 1,25(OH)2D levels in rats treated with cadmium for 90 days [134], as 
compared to non-exposed controls. Sacco-Gibson and colleagues did not find any 
change in 1,25(OH)2D levels or in renal dysfunction in dogs exposed to cadmium for 
seven months, as compared to non-exposed controls, despite increased bone resorption 
(skeletal 45Ca release) [136]. In contrast, two experimental studies indicate lower levels 
of 1,25(OH)2D in serum and kidney in female rats exposed to cadmium at a level 
relevant to humans [114, 115]. Previous human studies are inconclusive [71, 73, 74].   
 
The results from Paper III may suggest that there is no general involvement of 
cadmium-induced kidney damage in the effects on bone. Thus, these effects on could 
be parallel events, or that the tubular dysfunction increases the excretion of calcium and 
phosphate, as shown in experimental studies [114, 136] and some [56, 62] but not all 
[53] human studies, where in turn increased losses of calcium may cause bone loss . 
However, cadmium may have a direct toxic effect on bone, possibly through 
accelerated differentiation of osteoclasts, causing higher bone resorption [61, 62, 70, 
136-141]. To compensate increased release of calcium from bone to the circulation, 
excess calcium is excreted in urine 
 
In conclusion, these results indicate that, even though there were clear associations 
between cadmium and bone- and kidney effect markers, the activation of 1,25(OH)2D 
seemed not to be affected. These findings add some light on the mechanism of 
cadmium-induced effects on bone.  
 
5.4 RETINOL, CADMIUM AND BONE 
In Paper IV, we assessed serum retinol concentrations in 606 women. The obtained 
concentrations (median 1.9 µmol/L, ranging from 0.97 to 4.3 µmol/L), were mainly 
within what is considered the normal range of 1-3 µmol/L [27], and similar to that 
observed in women in USA and Europe [142-145] but somewhat lower than those 
obtained in Swedish men [32, 146].  
 
The main characteristics of the women in relation to tertiles of serum retinol are shown 
in Paper IV. Women in the highest tertile were less often classified as never-smokers 
and being postmenopausal and had lower concentrations of bALP and osteocalcin as 
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compared to those in lowest tertile, while no difference was observed for BMD. No 
significant correlation was observed between serum retinol and urinary cadmium 
concentrations (p=0.87).  
 
In the multivariable-adjusted analysis serum retinol was significantly inversely 
associated with bALP and osteocalcin (p≤0.04), and was close to significantly 
positively associated with BMD (p=0.08) and PTH (p=0.07) but not with DPD 
(p=0.25). Urinary cadmium on the other hand, was still after including serum retinol in 
the models, inversely associated with BMD and PTH (p=0.01 for both) and with DPD 
(p<0.001), but not with bALP or osteocalcin (p=0.19 and p=0.40, respectively). 
Altogether, this indicates that retinol and cadmium may have contrasting effects on 
bone.  
 
We observed a tendency of a positive association between serum retinol and BMD. 
Null or weak associations have previously been observed for serum retinol or retinyl 
esters in relation to BMD or fracture risk [143-150]. Some studies have found retinol 
to be associated with higher BMD, or have shown that women with osteoporosis have 
lower retinol concentrations. In Paper IV, we found no indication of a U-shaped or 
non-linear relationship between vitamin A and the bone outcomes, as indicated in 
some previous studies [34, 35]. Although, the serum retinol concentrations in the 
present study were in the similar range as that observed in the two studies from 
Opotowsky and colleagues and Promislow and colleagues, although we only observed 
few women that had concentrations below 1 µmol/L or above 3 µmol/L, which may 
have compromised the possibility to observe any U-shaped relationship.  
 
We further evaluated the combined effect of serum retinol and urinary cadmium by 
categorizing serum retinol and cadmium into 2 groups: below (low) or above (high) the 
median (< and ≥1.9 µmol/L for serum retinol and < and ≥0.66 nmol/mmol creatinine 
for urinary cadmium). Women with serum retinol below the median in combination 
with cadmium above the median had lower BMD (p=0.016); as compared to those with 
combined elevated serum retinol and lower urinary cadmium (Figure 18A). We also 
stratified the analyses by smoking status (never/ever), as smoking is an additional 
source of cadmium exposure and adversely associated with BMD [5, 151], and may 
negatively affect the concentration of vitamin A [143, 152]. Among never-smoking 
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women, higher serum retinol (≥1.9 µmol/L) was associated with higher BMD 
independent of urinary cadmium levels (Figure 18B).  
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Multivariable-adjusted linear regression coefficient and 95% CI of BMD in relation 
to combined serum retinol (categorized into below (low, L) or above (high, H) the median; 1.9 
µmol/L) and urinary cadmium (categorized into below (low, L) or above (high, H) the median; 
0.66 nmol/mmol creatinine) among all women (A), never-smokers (B) and ever-smokers (C). 
Low serum retinol and high urinary cadmium constitute the reference category. Model was 
adjusted for age, BMI, menopausal status, season and physical activity. *Different from the 
reference category, p<0.05.  
 
Among ever-smoking women, no significant association was observed (Figure 18C), 
although there was a tendency of a higher BMD in women having high retinol and low 
cadmium.  
  
In conclusion, our findings may suggest the negative effect of cadmium on bone may 
be counteracted by vitamin A.  
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5.5 ADDITIONAL METHODOLOGICAL CONSIDERATIONS 
5.5.1 Study design 
Papers I-IV are based on cross-sectional data with the exception of the analysis of risk 
of fractures (ascertained from 1997 to 2009). In Paper I, fractures were ascertained 
both retrospectively and prospectively in relation to the urinary cadmium measured in 
2004-2008. In Paper II, fractures were ascertained prospectively in relation to dietary 
cadmium intake, estimated via the FFQ in 1997. It should be noted, however, that the 
study population in Paper I and II was defined by those who had provided urine 
samples in 2004 to 2008. 
 
The cross-sectional design is often used when the purpose is to describe a population or 
to estimate the prevalence, but not the incidence, of the outcome of interest at a certain 
time point. This design is also common in studies using biomarkers of exposure and/or 
effects. Nearly all studies assessing associations between cadmium and bone are of 
cross-sectional design. However, since both the exposure and the outcome are 
measured at the same time, it will hamper the inference with respect to causality. It 
could be argued that the use of urinary cadmium is somewhat different since this 
marker reflects the long-term kidney accumulation over decades. In a cross-sectional 
study, it is important that the participating subjects are representative of the population 
and a high participation rate is required to be able to generalize the findings to the 
general population. The participation rate was relatively high in the studies.  
 
With a prospective design the exposure is measured before the outcome is observed, 
which is an advantage as e.g. the diet is not affected by the disease (Paper II). In a 
retrospective design the outcome is first observed and then the exposure is estimated, 
although it seems unlikely that the urinary cadmium concentrations were affected by 
fracture status (Paper I).  
 
5.5.2 Selection bias 
Selection bias is a systematic error that may occur when the participating subject differ 
from those not participating. The bias may be introduced when the procedure choosing 
the participants differ, or when other factors influence the participation (Rothman, 
1998). High participation rate is therefore important. The participation rate in the 
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present studies varied between 60 and 70%, which generally is considered relatively 
high,. In Paper I and II, we were only able to include women who were recruited 
between 2004 and 2008 (no urine samples were collected before 2004 and recruitment 
continued until September 2009). The women recruited during 2009, did not differ in 
e.g. BMI from those included in this study, indicating that the slightly shorter 
recruitment period did not affect the representativness of women. For the whole sub-
cohort, however, we cannot exclude that women with limited mobility due to e.g. 
fractures were less likely to participate and that those who participated were healthier 
than those who did not participate. Nevertheless, about a similar prevalence of 
osteoporosis was observed in the studies as compared to the prevalence estimated in 
Swedish women of similar age [11].  
 
A systematic error may be introduced in prospective studies if there are differences in 
completeness of the follow-up between the exposed and unexposed. By computerized 
linkage to the National Patient Registry and regional fracture registries, we considered 
the follow-up of fractures virtually complete, minimizing the possibility that our results 
were biased by differential follow-up.  
 
5.5.3 Information bias 
Information bias occurs when measurements or classification of exposure or disease do 
not correctly measure what they are suppose to measure i.e. they are not valid. These 
errors may be introduced by the participants, by the instrument (laboratory or 
questionnaire) or by the observer. The main type of misclassification in this thesis 
which may affect the interpretation of exposure-disease is non-differential. This 
misclassification refers to errors in the measurement of exposure that are unrelated to 
the disease, or errors in classification of disease that are unrelated to the exposure. 
Thus, if this misclassification does not differ between the exposed or unexposed or with 
or without the outcome, this would mainly give rise to underestimation of the strength 
of the association. 
 
Random and systematic errors  
There is always a possibility of random errors in quantitative research. If random errors 
are lacking, then the precision is high. Precision depends mostly upon sample size but 
also on the quality of the data. Although our study is one of the largest using 
biomarkers of cadmium exposure (i.e. adequately powered) and at the same time 
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having a high analytical accuracy, the number of cases was limited in some analysis 
resulting in wide confidence intervals. Systematic errors in turn are not dependent upon 
sample size or chance, but rather a methodological error that may occur when selecting 
the study participants.   
 
Misclassification of exposure 
To minimize exposure misclassification, all analyses were performed with a high 
analytical accuracy (see Methods). Both urinary and dietary cadmium may be prone to 
misclassification. In Paper I and II, we choose a cut-off <70 years in order to decrease 
the risk of distortion of the urinary cadmium concentration that may occur in older age 
[84]. In Paper III and IV all women were below 64 year of age. In any case, this most 
likely attenuates the observed associations.  
 
We performed several sensitivity analyses with regard to urinary cadmium in order to 
test the robustness of the results. First we excluded subjects that had extreme creatinine 
concentrations (outside 0.3 and 3.0 g/L, n=65), which had only marginal effects on the 
estimates. Very low creatinine concentrations (a sign of low muscle mass) leads to 
higher creatinine-adjusted urinary cadmium concentration, while a very high creatinine 
concentration give rise to lower adjusted urinary cadmium concentrations. In additional 
analysis, the creatinine concentration was included as covariate in the multivariable-
adjusted models (together with creatinine-adjusted cadmium) to account for some 
additional explanation of creatinine; again, this had no effect on the estimates. 
Secondly, we adjusted urinary cadmium to mean urinary density instead of creatinine in 
order to minimize a possible effect of muscle mass; also this approach had marginal 
effect on the estimates.  
 
There is always a risk that the results are dependent on how the exposure categories are 
chosen. In Paper I, several attempts were made to explore possible effects of the 
categorization. The exposure (i.e. urinary cadmium) was included either as continuous 
variable, categorized in predetermined exposure categories or into tertiles. The results 
showed that the analyses were very robust. With regard to the estimated dietary 
cadmium exposure, misclassification is inevitable with this kind of methods, due to 
error in self-reports and due to normal within-person variation in intake over time [153, 
154] (see page 49-50 for more details). Since Paper II is a prospective study and any 
measurement error that would result in misclassification is unrelated to the outcome, 
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this would produce non-differential misclassification. Thus, this would most likely lead 
to an underestimation of the true relationship. 
 
Misclassification of outcome 
Misclassification of outcome may also occur. The use of a phantom and the high 
precision in the BMD measurements ensured a high validity. The consistency in the 
results between the different skeletal sites measured; support a low degree of 
misclassification of the outcome. Since fractures were obtained from registries (Paper I 
and II) with nearly 100% case ascertainment this misclassification is most likely 
minimal. Also the 1,25(OH)D concentrations in serum may be prone to 
misclassification. However, the control samples were within the recommended values 
and the CV was low, indicating that this misclassification should be rather low.  
 
5.5.4 Confounding 
In Paper I-IV, potential confounders were chosen based on whether they were 
associated with both the exposure and outcome, changed the estimate more than 10% in 
the model, or were generally accepted risk- or protective factors. Age and tobacco 
smoking are examples of very important confounders, clearly associated with both 
exposure and with the effect. A major advantage with the studies in this thesis is that 
we were able to control for several potential confounders. Confounders may also be 
misclassified and several strategies were undertaken to decrease the level of 
misclassification: For instance in order to be classified as being a never-smoker, the 
women had to report that they had never smoked in at least two separate questionnaires. 
On the other hand, combining former and current smokers into one category (instead of 
using two separate categories or pack-years) may have led to residual confounding, but 
was done in order not to over load the statistical models and because the main focus 
was on never-smokers. On the other hand, as the distinction between former smoking 
and current smoking is not fully evident, misclassification may persist even if smokers 
were categorized into three groups. 
 
5.5.5 Generalizability 
The participants in the SMC and WHILA study are from the general population of 
Central and Southern Sweden. The relatively high participation rate indicates that the 
results are generalizable to the middle-aged female Swedish population.   
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6 CONCLUSIONS 
 
 Cadmium in urine, a marker of long-term exposure, was associated with lower 
BMD and increased risk of osteoporosis and fractures in Swedish women. The 
associations were independent of tobacco smoking, indicating that cadmium from 
the diet alone contributes to the risk. 
 
 Dietary cadmium exposure, estimated via a food frequency questionnaire, was 
associated with lower BMD and increased risk of osteoporosis and fractures. These 
associations were partly masked by dietary factors important for bone health and 
cadmium bioavailability. 
 
 Women with combined high dietary and urinary cadmium had lower BMD and a 
more pronounced increased risk of osteoporosis and fractures, indicating an 
underestimation of the risk in the separate analysis of urinary or dietary cadmium.  
 
 We found no support for cadmium-associated bone effects being mediated via 
lower concentrations of 1,25(OH)2D. 
 
 Serum retinol seemed to counteract some of the negative effects of cadmium on 
bone. 
 
 
These findings are of high public health relevance as cadmium exposure is 
prevalent and osteoporotic fractures substantially contribute to the total burden of 
disease. Moreover, the exposure occurs mainly via valuable foods such as whole-
grain cereals, vegetables and potatoes. The associations occurred at lower 
exposures than previously observed, providing support for revision of the existing 
health risk assessment. 
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7 FUTURE RESEARCH 
The present research has increased the knowledge on the association between cadmium 
exposure and bone effects in the general population. Future research should include: 
 
 Experimental studies are needed to increase the understanding on the 
mechanism(s) of the effects on bone. 
 
 A meta-analysis should be performed to summarise the evidence from all studies 
and to evaluate the dose-response relationship between urinary cadmium and bone. 
This is necessary to be able to set a “reference point” for bone effects that may be 
used in future health risk assessments. 
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Kadmium är ett metalliskt grundämne naturligt förekommande jordskorpan. Tillförseln 
av kadmium till åkermark sker via nedfall från luften (från tex metalltillverkning, 
förbränning av fossila bränslen, sopförbränning etc.) och genom gödsling 
(handelsgödsel och rötslam). Kadmium tas lätt tas upp i växter via rotsystemet vilket 
gör att kosten är den huvudsakliga exponeringskällan för de flesta människor. Höga 
halter av kadmium återfinns i födoämnen som skaldjur, inälvsmat och vissa fröer. Det 
största bidraget till exponering sker dock via våra viktigaste baslivsmedel såsom 
spannmålsprodukter, potatis och grönsaker och rotfrukter. Rökare exponeras ytterligare 
för kadmium via tobaksrök.  Kadmium ansamlas i kroppen, främst i njuren. Det är 
sedan länge känt att kadmium orsakar skador på njurarna. Vid massiv exponering har 
man även sett att kadmium orsakar skelettskador med frakturer som följd. Några få 
studier talar för att även en mycket lägre exponering dvs den exponering som 
förekommer i den allmänna befolkningen kan påverka benhälsan och möjligen öka 
risken för benskörhet. Sambanden är dock ofullständigt klarlagda. 
 
Benskörhet kallas “den tysta epidemin” då den utvecklas långsamt och ger inga 
symptom innan den första frakturen uppstår. Benskörhetsfrakturer utgör ett stort 
folkhälsoproblem som orsakar mycket lidande och höga kostnader för samhället, vilket 
belyser behovet av prevention. Varannan kvinna och var fjärde man förväntas att 
drabbas av en benskörhetsfraktur under sin livstid. Varje år beräknas 70 000 
benskörhetsfraktur inträffa i Sverige till en kostnad över 5.6 miljarder, enbart inkluderat 
sjukvårdskostnader. Det beräknas att endast hälften av de som drabbas av en höftfraktur 
återvänder till ett självständigt liv. Dödligheten efter en höftfraktur ligger mellan 10-
15%. Det är stora geografiska skillnader i insjuknandet i höftfrakturer, sannolikenheten 
är mer än sjufaldigt högre att drabbas i norra Europa, speciellt i Sverige och Norge, än i 
övriga Europa.  
 
Syftet med denna avhandling var att undersöka effekterna av långsiktig låggradig 
kadmiumexponering på benhälsan, och utröna om dessa effekter uppkommer via 
minskad aktivering av vitamin D i njuren. Ett annat syfte var att belysa möjlig 
kombinerade effekt av kadmium och vitamin A på ben. Två befolkningsbaserade 
studier användes som består av kvinnor, 54 till 69 år: Den Svenska 
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Mammografikohorten (SMC) i Uppsala och Kvinnors Hälsa i Lundabygden (WHILA). 
Kvinnornas kadmiumexponering bestämdes genom analys av kadmiumhalten i urin, 
vilket reflekterar den kroniska exponeringen, och genom att uppskatta kadmiumintaget 
via en kostenkät. Kvinnornas bentäthet mättes i flera olika delar i kroppen med hjälp av 
röntgenteknik (DXA). Dessutom har information om frakturer inhämtats via 
frakturregister. Vitamin D och vitamin A analyserades i serum.  
 
Resultaten visade tydliga negativa samband mellan kadmium och bentäthet i 
helkroppen, lårbenshalsen, höften och i ländryggen, dvs med ökande 
kadmiumexponering så minskar bentätheten. Vi fann också samband mellan 
kadmiumexponering och ökad risk att drabbas av benskörhet och frakturer. Samtliga 
samband var oberoende av tobaksrökning. Vidare fann vi inget belägg för att kadmium 
stör vitamin D-aktiveringen i njuren. Vitamin A verkade delvis  motverka kadmiums 
negativa effekt på ben. Anmärkningsvärt var att sambanden kunde påvisas vid låg 
exponering dvs den exponering som återfinns i den allmänna befolkningen 
 
Sammanfattningsvis så bidrar denna avhandling med viktig information om kadmiums 
negativa effekt på ben med både ökad risk för benskörhet och frakturer. Dessa fynd är 
av hög relevans eftersom alla är exponerade för kadmium, den huvudsakliga 
exponeringen sker via våra viktigaste livsmedel och det finns inga tecken på att 
exponeringen minskar. Dessutom utgör benskörhetsfrakturer ett stort folkhälsoproblem. 
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